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The publication of the research paper in 1997 on the cloning of the first animal 
from an adult cell – Dolly the sheep – caused a scientific and media storm. The 
scientific breakthrough, long thought to be impossible, was achieved by a small 
team from Roslin Institute led by Ian Wilmut together with colleagues from its 
spin off company PPL Therapeutics.
This is a transcript of a Collective Memory Event held on the 19th April 2016 
with members of the team and other colleagues closely involved. Of course, al-
though 1997 is seen as the date of the publication of the research, its origins lie 
much earlier, not only with the birth of Dolly in 1996, the cloning of Megan and 
Morag from embryo cells in 1995, but also with the long standing interest of Ian 
Wilmut and his group in the potential totipotency of somatic cells and in the 
derivation of stem cells. Indeed, I first heard in detail of Ian’s research objectives 
in December 1988, a few days after I became Head of Roslin,i nearly a decade be-
fore the publication.
The question I was most asked at the time was ‘why is Roslin doing this re-
search?’ It appeared strange, if not incomprehensible, for a small agriculturally-
oriented Institute in Scotland to be working on such a challenging topic, which 
seemed, at first glance, to have no practical relevance. In the late 1980s and early 
1990s, the molecular biology revolution was sweeping through biological re-
search. The first genetically modified / transgenic animal (a mouse) had been pro-
duced and the beginnings of the genomics revolution were in place. Roslin, like 
many other biological research institutes, decided it had to adopt these technolo-
gies, especially as no one else was doing so in farm animals, which is where Ros-
lin’s expertise lay. Transgenic sheep had been produced in Roslin and a company, 
PPL Therapeutics, ii was established to exploit the technology, although prima-
rily in producing pharmaceuticals rather than for animal breeding. Fortunately 
as a government sponsored Institute, Roslin (in collaboration with John Innes 
Institute) managed to persuade their parent organisation and main funder, the 
BBSRC,iii to establish decade-long research programmes in transgenics and stem 
cells, and in gene mapping and genomics.
For routine use in animal breeding, there were problems with transgenic tech-
nology, especially that it was too inefficient. Less than one per cent of injected 
eggs produced viable transgenic offspring and almost all commercially important 
traits in farm animals are controlled by many genes, whose number, identity and 
characteristics are all unknown.iv It was to improve transgenic technology that 
Ian Wilmut proposed using nuclear transfer from somatic cells; the programme 
was funded under the new BBSRC initiative and Keith Campbell was appointed 
as the post-doc on the project. The first cells targeted were from a stable embryo 
cell line isolated by Jim McWhir, and produced Megan and Morag, the first cloned 
sheep, in 1995. Next year, the group’s main aims were to repeat the experiment 
with embryo cells but also foetal fibroblasts, which they thought to be the most 
suitable cells for manipulation. It was only because extra sheep were available and 
a suitable mammary cell line had been produced at PPL, that the team had adult 
cells that could be used to produce Dolly.
This Collective Memory Event brings together most of the scientists involved 
in the experiments: Ian Wilmut who led the team, Bill Ritchie who carried out 
the embryo manipulations and John Bracken who cared for the animals, together 
with scientists from PPL Therapeutics, Alan Colman, its Research Director, and 
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Angelica Schnieke who produced the mammary cell line. They are joined by oth-
er Roslin colleagues: Harry Griffin who was at the time Assistant Director of Sci-
ence (and later Director); Alan Archibald, leading Roslin’s genomics programme; 
Bruce Whitelaw leading mammalian transgenics; and Helen Sang leading poultry 
transgenics. The event was chaired by Robin Lovell-Badge, a leading figure in 
transgenesis who was also a member of the Roslin Governing Council at the time 
when these events took place. These are then the genuine voices of what hap-
pened at Roslin in the mid-1990s and their recollections make a fascinating story 
of not only the scientific research but also the complex interactions that took 
place. It is only so very sad that John Clark and Keith Campbell, so much leading 
players in these events, were no longer with us and able to take part.
The cloning of Dolly was in some ways a diversion from what Roslin was 
trying to achieve; later experiments did in fact produce cloned animals from 
manipulated foetal fibroblasts cells with working human genes and capable 
of producing pharmaceuticals, but this success got lost in the furore of Dolly’s 
arrival. Although the farm animal genomics programmes have now identified 
many genes controlling commercially important traits, the political climate has 
strongly inhibited the use of GM technology in practical animal breeding.
The Dolly publication also generated much public, media and government in-
terest. Roslin was overwhelmed with TV crews and request for interviews; myself 
and Ian Wilmut were called to a special meeting of the House of Commons Select 
Committee on Science and Technology that was squeezed in a few weeks later, 
just before the 1997 General Election. The ethics of the technology were debated 
at the Human Genetics Advisory Commission in the UK and at by various bod-
ies in the EU, USA and the rest of the world. One positive side of all this atten-
tion was that Roslin’s policy of openness about its research (mainly executed by 
Harry Griffin) turned out to be very successful and Roslin became seen as a ‘safe 
pair of hands’; we were asked for our opinion by the media and Government on 
many biotechnology issues, not all in our area of expertise. This interest contin-
ues up to the present.
In 1998 Roslin established a second company, Roslin BioMed, with £6 M of 
funding from the 3i Venture Capital Group, in order to develop the cloning tech-
nology. It was the multimillion pound sale of Roslin Biomed to the Californian 
biotech company, Geron, that stimulated more political interest. Roslin affairs 
were examined by the National Audit Office; myself and Harry Griffin had to at-
tend the House of Commons Public Accounts Committee to explain and justify 
our actions. The money Roslin received from the sale to Geron was put into a 
Foundation, which continues to fund research at Roslin.
The story of ‘Dolly the Sheep’ is one of a formidable piece of research with 
a seemingly impossible objective, outstanding success from the persistence and 
skill of an excellent team of scientists, to its explosion into the public domain 
which engulfed those involved, producing many lessons, not only of science 
strategy, but also of the role of scientists in their interaction with commercial 
companies, the Government and the public; the voices of those involved add 
much to the story.
i. I have used the name Roslin Institute throughout this foreword, but although its origins go 
back to 1919, the Institute only adopted its current name in 1993.
ii. PPL Therapeutics Ltd. was founded in 1987 as Caledonian Transgenics, but was soon re-
named Pharmaceutical Proteins, Limited, and eventually, PPL.
iii. The Biotechnology and Biological Sciences Research Council (BBSRC), the ‘owners’ of Ros-
lin Institute at this time, was only founded in 1994, although its origins go back to the forma-
tion of the Agricultural Research Council in the 1930s.
iv. A solution to the gene identity problem came from the genomics programmes.
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Introduction
DMItRIy MyeLnIkov & MIGueL GARCÍA-SAnCHo
Science, Technology & Innovation Studies, 
The University of Edinburgh 
Born on 5 July 1996, Dolly the sheep was the first animal to be cloned from an 
adult cell, and became the most iconic member of her species. Many accounts of 
her creation already exist, authored by some of the scientists involved as well as 
journalists and social scientists.i As part of the BBSRC-funded ‘Historicising Dol-
ly’ project at the University of Edinburgh, we sought to conduct a group memory 
event that would gather different members of Roslin Institute and PPL Thera-
peutics who were either involved in the cloning or observed it as colleagues. Our 
purpose was twofold. First, we sought to place Dolly within the broader genetic 
engineering research programme at Roslin, alongside other cloned and trans-
genic sheep made there, and in the historical context of 1990s biotechnology and 
science funding. Second, through a collective memory event, we hoped to gather 
diverse perspectives and allow the participants to reflect on the established nar-
ratives together. What follows is a brief introduction to the Roslin Institute and 
some of the key experiments discussed here, which should help the reader follow 
the transcript. 
from ABRo to Roslin
Roslin Institute traces its history to the Animal Breeding Research Department at 
the University of Edinburgh, set up in 1919 with F. A. E. Crew as its first director. 
It soon became the Institute of Animal Genetics and was a major site in the bud-
ding discipline of genetics, with focus on farm as well as laboratory animal he-
redity. After World War II, the UK Agricultural Research Council (ARC) founded 
the Animal Breeding Research Organisation (ABRO) on the basis of the Institute. 
ABRO’s mission was to pursue basic and applied research into farm animals to 
improve breeding programmes in the nation. The organisation was showing a 
steady growth into the 1970s, when the reforms following the split its funding 
between the block grant from the ARC and research contracted by the Ministry 
of Agriculture, Fisheries and Food. The split stemmed from Lord Rothschild’s 
controversial 1971 report that became government policy under Edward Heath, 
instilling a ‘customer-contractor’ principle on applied R&D. 
In 1982, ABRO faced a serious crisis. The ARC, eager to pursue biotechnol-
ogy research and make savings, threatened an 80% cut to the Organisation. The 
proposal was met with resistance, and farm groups, media outlets and a few MPs 
rallied to support the Organisation; eventually, ABRO lost about 50% of its funds, 
but promised to reorient its research towards genetic modification. Serious cuts 
to the ARC under Margaret Thatcher’s government followed shortly after, and 
many council institutes were merged, shut down or privatised. While ABRO 
was spared the more dramatic fate, in 1986 it was merged with the Roslin-based 
Poultry Research Centre, and the Babraham Institute of Animal Physiology near 
Cambridge. The new mammoth Institute of Animal Physiology and Genetic Re-
search (IAPGR), with an Edinburgh and Cambridge Research Stations, lived for 
eight years, and was split into Babraham and Roslin Institutes in 1993. By then, 
the Edinburgh scientists had consolidated their research at a former Poultry Re-
search Site in the village of Roslin. In 2008, the Institute was incorporated into 
the University of Edinburgh, and in 2011 moved into a brand new building at the 
Easter Bush Campus just outside Roslin
vFrom pharming to cloning
As part of the 1982 settlement with the ARC, ABRO embraced genetic modifica-
tion and hired scientists with expertise in molecular biology. By that point, ge-
netically modified or transgenic mice, first reported in 1980, were being adopted 
by labs across the globe, and there were hopes that similar techniques could be 
applied to farm animals. Rick Lathe, who had worked at a biotechnology com-
pany Transgéne in Strasbourg, was hired in 1984. Together with John Bishop at 
the Department of Genetics, and John Clark, Bishop’s post-doc, Lathe devised the 
programme of making transgenic sheep. Rather than focus on improving breeds 
with genes – a prospect that was proving difficult for key US groups – Lathe and 
Bishop pursued production of pharmaceutical proteins in milk instead. The idea 
echoed the business model of new US biotechnology firms like Genentech, which 
pursued protein production in bacteria. For Lathe, farm animals offered two 
advantages: some human proteins could not be processed properly in bacterial 
cells, and milk production promised high yields. This idea came to be known as 
‘pharming’ (portmanteau of ‘pharmaceuticals’ and ‘farming’).
Lathe left ABRO shortly after, in 1986, and John Clark took over the pro-
gramme. By that point, transgenesis in sheep had not been achieved anywhere, 
and serious embryological expertise was required (see Fig. 1). Ian Wilmut, who 
had joined ABRO in 1973, was diverted from his research on prenatal mortality to 
help with embryo injections and transfer, and Paul Simons was hired to perform 
the hands-on manipulations. Alan Archibald, another ABRO scientists who had 
recently trained in molecular skills at the European Molecular Biology Labora-
tory in Heidelberg, made many of the gene constructs. 
Meanwhile, faced with funding gaps, ABRO management sought to seek pri-
vate investment, in line with Thatcherite science policy. With the help of the 
Scottish Development Agency, a local body set up with North Sea oil money to 
boost business in Scotland, and private investment funds, a new company was 
The pharming programme
The diagram in Figure 1 shows how to make phar-
maceutical proteins in sheep milk (‘pharming’). A 
human gene of interest — for example, the gene for 
alpha-1-antitrypsin, an emphysema drug that PPL 
pursued — that had been isolated and spliced with 
sheep enhancer (E) and promoter (P). These are 
the DNA elements that regulate gene expression, 
i. e. how much protein is made from DNA, and in 
which tissue – here, the mammary tissue is targeted 
to make the protein in milk. The human/sheep 
construct is inserted into a circular bacterial DNA 
molecule, or plasmid, which is taken up by bacterial 
cells, and multiplies in them as the bacterial colony 
grows. The modified plasmid can then be purified, 
and the compound human-sheep gene isolated. This 
resulting DNA molecule can then be microinjected 
into the shep embryo at a 1-cell stage, i.e. a ferti-
lised sheep egg. The injection happens into one of 
the pronuclei – a sperm or egg nucleus that do not 
merge until the embryo divides for the firtst time. If 
things go well, the resulting sheep will be transgenic, 
or carry the inserted gene and make the desired 
protein in its milk. 
Figure 1. Diagram showing 
the making of transgenic 
sheep, from the ABRO 1985 
annual report, p. 22. Courtesy 
of the Main Library, Univer-
sity of Edinburgh. 
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founded in 1987 to commercialise pharming. First called Caledonian Transgen-
ics, it soon changed its name to Pharmaceutical Proteins Limited, or PPL. PPL 
funded considerable amounts of the molecular research at ABRO’s successors, 
IAPGR and Roslin Institute, in exchange for licensing the patents, and set up its 
own research programmes in parallel. 
In 1990, the pharming programme celebrated its first big success, as Tracy 
the sheep was born at Roslin. While not the first transgenic sheep to be made, 
Tracy produced vast amounts of alpha-1-antitripsin, a protein used in treatment 
of emphysema and cystic fibrosis, in her milk. Despite this success, production 
of transgenic sheep remained difficult, slow and expensive, many manipulated 
embryos did not deliver, and where the foreign DNA would integrate within the 
sheep genome was left to chance. Again, mouse researchers paved the way. In 
1989, a first ‘knockout’ mouse was born, which had a gene removed rather than 
added. The result was made possible by using embryonic stem cells – first cul-
tured in 1981 – that could be manipulated in culture, with a lot more ease and 
reliability. Sheep embryonic stem cells were not available, but in the early 1990s, 
Roslin and PPL invested considerable resources in working with cultured cells.  
The project to clone sheep from somatic, i. e. differentiated body cells devel-
oped from this interest, and envisioned cloning as a way to reproduce success-
fully modified sheep without access to stem cells. While Dolly was not genetically 
modified, a sheep called Polly was born in 1997, both cloned and transgenic. In a 
sense, Dolly was a prototype, and Polly the pinnacle of the project, but this sec-
ond birth was eclipsed by the furore that was Dolly. Yet, as this transcript makes 
clear, there were other interests at play in the making of Dolly. Thus, the Min-
istry of Agriculture, Fisheries and Food (MAFF) sponsored a significant part of 
the research, but was eager to keep at an arms length from controversial and 
commercially-oriented genetic engineering. Instead, applications to the Ministry 
emphasised potential of reproductive cloning of valuable farm animals. Finally, 
the scientists at Roslin were also interested in what cloning could reveal about 
embryonic development and differentiation.
Cloning
Cloning has been a charged and fascinating topic for biology and its various pub-
lics. In 1952, Robert Briggs and Thomas King, based at the Institute for Cancer 
Research of the Lankenau Hospital Research Institute near Philadelphia, cloned 
a frog Rana pipiens from undifferentiated embryonic cells. They relied on nuclear 
transfer – transplantation of a cell nucleus into a recipient egg cell whose nucleus 
had been removed. In 1959, using a different frog species, Xenopus laevis, John 
Gurdon at Oxford University managed to clone frogs from differentiated tadpole 
cells. These experiments answered important questions about how genes persist-
ed in development, suggesting cells did not lose genetic material as they divided, 
but rather that differentiation was achieved by switching genes on and off. 
Cloning in mammals, however, proved difficult. In 1981, Karl Illmensee at the 
University of Geneva reported cloning three mice from embryonic cells, but af-
ter allegations of fraud from within his team this claim was dismissed. New dis-
coveries about parental imprinting – the idea that both paternal and maternal 
chromosomes contributed crucial epigenetic information, and thus both were 
necessary for successful development – were being made in the early 1980s, and 
cloning from adult cells seemed unlikely. Yet while there were many setbacks 
in mice, nuclear transfer was increasingly promising in agriculture. At the Cam-
bridge Animal Research Station,ii Steen Willadsen cloned a sheep from early em-
bryonic cells and published the result in 1985. At the University of Wisconsin, 
Neal First’s group paved the way with cloning cattle from embryonic cells. 
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Roslin succeeded in cloning sheep from cultured 
embryonic cells in 1995, when Megan and Morag 
were born, to a significant, but mostly forgotten, con-
troversy. They were made from the TNT cell line that 
offered a promise of genetic manipulation. Following 
these experiments, Roslin and PPL scientists pursued 
other kinds of sheep cells – foetal fibroblasts and 
mammary cells – to confirm whether a cell's embry-
onic status was essential for the procedure. In 1996, 
Dolly was made from a nucleus that came from the 
mammary cells of a Finn Dorset sheep – long dead 
by then – that was transplanted into an enucleated 
oocyte of a Scottish Blackface sheep. The nucleus 
and oocyte were fused with an electric pulse, and the 
resulting embryo was implanted into another Scot-
tish Blackface surrogate mother. 
On 5 July 1996, Dolly was born. While the scientists 
were ascertaining her genetic origins and writing up 
the paper, she was kept secret, even from most staff 
at Roslin, as this transcript shows.   
Legacy
Dolly was due to be announced on 27 February 1997, to coincide with the pub-
lication of the scientific paper in Nature. The Observer broke the news a few days 
early, on 22 February, derailing Roslin and PPL's careful publicity plans that had 
been organised by the PR firm De Facto. The havoc that ensued was driven by 
immediate associations with human cloning, and it was fuelled by government 
interest in both the UK and the United States – Bill Clinton's newly-appointed 
head of the National Bioethics Advisory Commission was among the first peo-
ple to phone Roslin. Multiple ethical reports condemning human cloning were 
published, and the UK parliament rushed to adjust the Human Embryology and 
Fertilisation Act to explicitly ban human cloning. 
 At first, the controversy seemed dangerous for Roslin. Ethical concerns made 
scientists worry that cloning experiments could be banned altogether. MAFF, al-
ready reluctant to deal with genetic modification and weary of the controversy, 
had rushed its plan to shut down funding for cloning at Roslin. Yet despite this 
initial uncertainty, the Institute used Dolly to its maximum advantage. Grahame 
Bulfield appealed to the scientific press and MPs about the defunding of what 
emerged as a key site for global biology, and MAFF reversed its decision. The 
patents derived from cloning – the cell culture methods rather than the nuclear 
transfer per se – were not covered by the agreement with PPL, and Roslin de-
cided to exploit them more aggressively. A new company, Roslin Biomed, was 
established in 1998 and sold to the US biotech firm Geron the next year. The deal 
funnelled much-needed investment into the Institute, ending years of austerity. 
Finally, Dolly herself proved an asset. Friendly and happy to engage with humans 
– as she learned to expect a treat in return – Dolly came to represent a softer edge 
of biotechnology. 
This transcript adds to the existing narratives around Roslin in several ways. 
First, it highlights the roots of the cloning programme within pharming and 
shows that they stemmed from the 1980s policies about agricultural science. It 
hints at alternative research programmes – making pharmaceuticals in eggs, for 
example – and highlights collaboration both within Roslin and between the In-
stitute and PPL. Finally, it offers multiple perspectives on the legacy of Dolly's 
fIGuRe 2. Dolly shortly after 
her birth, a Finn Dorset lamb 
next to her Scottish Blackface 
surrogate mother. 
© Roslin Institute.
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birth for Roslin, but also for agricultural sciences, biomedical research, the bio-
tech industry and the science-media relations.   
note on the transcript
The event transcribed here took place on 19 April 2016, in the picturesque Elder 
Room, Old College, University of Edinburgh. The method we pursued was that of 
a witness seminar, which aims to bring together multiple perspectives as partici-
pants share, question and clarify their memories, with minimal interference. The 
Wellcome Trust Witnesses to Twentieth-Century Medicine series, organised and 
edited by Tilli Tansey and her team, was the major inspiration.iii This event was 
different in that it focused on a single institution rather than a field. We decided 
to limit the audience to the scientists and technicians from Roslin and not invite 
external participants such as journalists involved in announcing Dolly, to create 
a relaxed atmosphere where the witnesses would not be immediately encouraged 
to adopt a public-facing persona. 
The event went on for about four hours, split in two sessions. The conversa-
tions was recorded and transcribed, and the transcript sent to participants for 
edits and clarifications. We have then incorporated their (very minor) changes 
into this version, alongside light editing for style and clarity, trying to maintain 
the conversational nature of the event while making it easy to follow as written 
prose. The opinions of the speakers are their own. 
The text is annotated in two ways. Endnotes are used to cite the literature, 
clarify certain passages and offer context. In parallel, definitions of the more ob-
scure scientific terms are given in the margins the first time they appear in text. 
Despite the occasional esoteric passage, we hope that this transcript can do some 
justice to the palpable excitement that was felt on the day of the event.
i. An account of Dolly’s cloning co-authored by Ian Wilmut and Keith Campbell, the team 
leaders, was published as Ian Wilmut, Keith Campbell & Colin Tudge, The Second Creation: 
Dolly and the Age of Biological Control (Cambridge, MA: Harvard University Press, 2001). 
For a journalist investigation published very shortly after Dolly became public knowledge, 
see Gina Kolata, Clone: The Road to Dolly and the Path Ahead (London: Penguin, 1998). 
For an anthropologist's perspective that places Dolly in multiple contexts, from biocapital 
to imperialism, see Sarah Franklin, Dolly Mixtures: The Remaking of Genealogy (Durham, 
NC: Duke University Press, 2007). Various sources and essays on cloning are collated in 
Arlene Judith Klotzko (ed.), The Cloning Sourcebook (Oxford: Oxford University Press, 
2001). For a historical account that situates Dolly within the genetic engineering pro-
gramme at Roslin, see Miguel García-Sancho, ‘Animal Breeding in the Age of Biotechnol-
ogy: The Investigative Pathway behind the Cloning of Dolly the Sheep,’ History and Phi-
losophy of the Life Sciences, 37 no. 3 (2015): 282–304. On the history of Roslin's precursor 
institutions and the 1980s cuts, see Dmitriy Myelnikov, ‘Cuts and the Cutting Edge: Brit-
ish Science Funding and the Making of Animal Biotechnology in 1980s Edinburgh,’ Brit-
ish Journal for the History of Science (forthcoming); see also the Towards Dolly archive blog 
http://libraryblogs.is.ed.ac.uk/towardsdolly, last accessed on 3 April 2017.
ii. The Animal Research Station in Cambridge was an ARC unit where major work on develop-
mental biology in farm animals, as well as mice, took place. In 1986, in the merger with ABRO 
to make IAPGR, the Station was merged with the Babraham Institute of Animal Physiology 
and thus staff who remained became part of IAPGR. See Chris Polge, ‘The work of the Animal 
Research Station, Cambridge,’ Studies in History and Philosophy of Biological and Biomedical 
Sciences 38, no. 2 (2007): 511–520.
iii. On the witness seminar methodology, see E. M. Tansey, ‘Witnessing the Witnesses: Pitfalls 
and Potentials of the Witness Seminar in Twentieth Century Medicine,’ in Writing Recent Sci-
ence: The Historiography of Contemporary Science, Technology and Medicine, ed. Ron Doel & 
Thomas Soderqvist (London: Routledge, 2006), pp. 260–78; E. M. Tansey, ‘The Witness Semi-
nar Technique in Modern Medical History,’ in Social Determinants of Disease, ed. Harold J. 
Cook, Sanjoy Bhattacharya & Anne Hardy (Telangana: Orient Longman, 2009), pp.  279–295. 
See catalogue of available witness seminars at www.histmodbiomed.org/article/wellcome-
witnesses-volumes/, last accessed on 3 April 2017. 
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Timeline of key events
1947 Animal Breeding and Genetics Research Organisation is founded by the Agri-
cultural Research Council (ARC) on the basis of the Institue of Animal Genetics. 
Renamed Animal Breeding Research Organisation (ABRO) in 1951.
1981–82 The ARC proposes an 80% cut at ABRO, driven by budgetary pressures and wish 
to free more funds for high-priority research, including biotechnology. After 
much resistance, about 50% of ABRO is cut, but extra funding is made available 
for genetic engineering research.
1983 The ARC becomes the Agricultural and Food Research Council (AFRC).
1986 With further cuts to AFRC, ABRO is merged with the Poultry Research Centre in 
Roslin, and the Babraham Institute of Animal Physiology in Cambridgeshire, to 
form the Institue of Animal Physiology and Genetics Research (IAPGR).  
1987 Caledonian Transgenics Ltd. is set up to commercialise pharming research in 
Edinburgh. It soon becomes Pharmaceutical Proteins Limited (PPL). 
1990 Tracy the transgenic sheep is born at IAPGR.
1993 Roslin Institute is established after IAPGR is split.
1994 AFRC is merged with parts of the Science and Engineering Research Council to 
become the Biotechnology and Biological Sciences Research Council (BBSRC).
1995 Megan and Morag are cloned from cultured emrbyonic cells.
5 July 1996 Dolly the Sheep is born. Her cloning is kept secret until publication.
22 February 1997 Dolly is announced by The Observer, days before the scientific article is due to ap-
pear in Nature. Media frenzy ensues.   
1997 Polly and Molly, who are both cloned and transgenic, are born at Roslin.
1998 Roslin BioMed is founded to commercialise cloning and related techniques. 
1999 Roslin BioMed is sold to Geron, a US biotechnology company.
2003 Dolly is put down after she develops jaagsiekte (viral lung cancer).
2008 Roslin Institute becomes part of the University of Edinburgh.
xAlan Archibald was one of the ABRO 
scientists to adopt molecular tools in 
the 1980s, and was closely involved in 
the pharming programme and the Pig 
Genome Project. He is currently the 
Deputy Director at Roslin.
John Bracken was an animal carer and 
anaesthetist at Dryden farm, Roslin 
Institute, and looked after Dolly since 
her birth. He is currently retired. 
Alan Colman was the Research Direc-
tor at PPL Therapeutics. He is cur-
rently a Visiting Fellow at Harvard 
University. 
Harry Griffin was the Assistant Di-
rector for Science at Roslin, and one 
of the spokespeople for the intsitute 
when Dolly became public. He is cur-
rently retired. 
Robin Lovell-Badge chaired the event. 
He has worked with mouse embryonic 
stem cells and transgenesis, and was 
on the Roslin Governing Council. He is 
currently a greoup leader at the Crick 
Institute in London.  
Angelika Schnieke was a scientist at 
PPL Therapeutics and was involved in 
devising the cell line used for Dolly’s 
cloning. She is currently Professor of 
Livestock Biotechnology at the Tech-
niche Universität in Munich. 
Jim McWhir was a cell biologist at Ros-
lin, who was involved in culturing the 
cells for Dolly and other sheep. He is 
now retired. 
 
Bruce Whitelaw joined IAPGR in 1987 
and was involved in the pharming 
programme. He currently heads the 
Division of Developmental Biology at 
Roslin.
Bill Ritchie is an embryologist who per-
formed the micromanipulations for 
Dolly’s cloning. He is the founder of 
Roslin Embryology, Ltd.
Sir Ian Wilmut was the leader of the 
Roslin team that cloned Dolly. He is 
currently Professor Emeritus and Chair 
at the Scottish Centre for Regenerative 
Medicine, University of Edinburgh. 
Helen Sang joined the Poultry Re-
search Centre in 1984. She is an expert 
in genetic modification of poultry and 
Professor of Vertebrate Molecular De-
velopment at Roslin. 
fIGuRe 3. Participants on 
the day of the event.  
Left to right, Bruce Whitelaw, 
Alan Archibald, Bill Ritchie, 
Harry Griffin, Helen Sang, 
John Bracken, Miguel Garcia-
Sancho, Jim McWhir,  
Angelika Schnieke,  
Alan Colman, Ian Wilmut  
and Robin Lovell-Badge. 
© Dmitriy Myenikov
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1The transcript
1. Roslin, ppL, and the pharming programme
Robin Lovell-Badge. We need to try and get some ideas of the context that Dolly 
was created in. Obviously there are different aspects to this context and so there’s 
the various research that led up to the possibility of cloning animals. Beginning 
with frogs, and then there’s various bits of science done in various animals that 
gradually sort of progressed the field. In mice there were the rather dubious ex-
periments by Karl Illmensee, there were new methods developed by James Mc-
Grath and Davor Solter, which were obviously very instrumental.1 Of course 
there was the discovery of parental imprinting, which some people, in particular 
Solter, thought that would make it impossible to clone animals, or clone mam-
mals. Then there were people working in cows, like Neal First, and then there 
were people like Steen Willadsen, who did some early experiments trying to clone 
sheep, using nuclei from the early embryos.2 So that was actually in 1986, tak-
ing nuclei from 8- or 16-cell embryos and putting them into unfertilised oocytes, 
which was interesting, because most of the work that was going on, in mice at 
least, was trying to use fertilised eggs. So there are questions like why were sheep 
cloned first? The importance of the expertise at Roslin, collaborations, which we 
hope we will get from you.
I should also actually say at the outset that of course there are a few key people 
who aren’t here. Obviously some can’t be, and the two obvious ones are John 
Clark and Keith Campbell, so I think you said you would appreciate if anyone 
has views that they think those two individuals would have, to express them.3 
So, the first question that I was asked to put forward is ‘It’s sometimes said that 
the cloning of Dolly was an accident or a by-product, in the sense it took place 
within the pharming programme, and that programme sought the production of 
transgenic sheep. So why produce cloned sheep within a research programme that 
sought the genetic modification of animals?’ I don’t know who wants to tackle 
that question. Ian?
Ian Wilmut. Yes, I’ll have a go. There was actually a student who’d completed 
a PhD at Roslin, Lawrence Smith, he was from Canada. I guess he did similar 
things to First, he produced a very small number of lambs after nuclei transfer 
from early embryos... 
The initiative for the larger-scale, cloning project came, I think, when I heard at 
a meeting from a colleague of Willadsen’s, that he had successfully cloned from 
sheep blastocysts, but this was in ’89, I think, and the paper wasn’t published until 
2005, he presented it at the International Embryo Transfer Society. It seemed to 
me that it was almost certain that if he had cloned from blastocysts it would’ve 
been the inner cell mass, and of course around that time, the people who subse-
quently got Nobel Prizes for it,4 were doing lots of exciting things with embryo 
stem cells in the mouse, so that idea of having embryo stem cells was very much 
in in the general discussion. And it seemed to me that if we could achieve two 
things, get embryo stem cells from livestock and do nuclear transfer from them, it 
would present great opportunities, either for multiplication or for genetic modi-
fication. 
We probably just succeeded in handing on the gene transfer technology to PPL 
Therapeutics, and certainly I was being cut free, having been obliged to be in-
volved in the gene transfer project by Roger Land.5 The deal was that once the 
transfer project was completed, or up and running, that I could go away and do 
my own thing again, and it seemed to me, having worked with John Clark and the 
other molecular biologists I learnt a little bit at least from them, that to try and 
create an opportunity for making precise change in livestock would be a useful 
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2thing to do, a good thing to do. I’d never worked with Willadsen but I did know 
him, he succeeded me on a post in Cambridge when I came to Edinburgh, and 
I arranged to see him. By the time I heard about his work, which was done in 
Texas, he was in Calgary, and I happened to be going to Australia, later that year, 
and instead of going over Asia I went over America and on the way back called 
in to see Steen, and he was extremely generous with his ideas and his time, and 
confirmed that he had grown from cattle blastocysts, and described the technol-
ogy to me. And so when I got back to Edinburgh, I discussed with Roger starting 
projects in this area, and I guess it was probably Roger who steered the thing 
towards the DTI [Department of Trade and Industry] funding initiative, rather 
than seeking BBSRC funding for it, and that was certainly the way we went.6
Lovell-Badge. So the main motivation was the pharming idea?
Wilmut. No, more general genetic modification.
Miguel García-Sancho. Could you describe the work you’d been doing in Edin-
burgh before, since you arrived from Cambridge in 1973?7
Wilmut. The work that we did before the involvement in the molecular biology 
project was to try to understand the causes of prenatal mortality, by investigating 
the relationship between embryos and the mother. We did quite a lot of work, 
mostly in sheep, one experiment in pigs, which went quite a long way to suggest 
that a significant amount of prenatal mortality reflects physiological variation, 
the embryo and uterus get out of step even in the same mother. Unfortunately, 
we worked ourselves into a corner, because if you say that there are maybe four 
or five causes of prenatal mortality, so that they might each cause four or five 
per cent loss, if you want to try to demonstrate that that physiological variation 
is causing that loss, you have to be able to hold the circumstances in which the 
animals are breeding, and their nutrition and everything, stable and uniform and 
consistent, so that you can look at the effect and variation of the one thing that 
you’re looking at. And it’s not possible, it’s a Heisenberg uncertainty principle 
problem, so you can only suggest it as an interpretation.
Helen Sang. Can I just ask quickly? Was this all to do with farm animal repro-
duction or was it modelling for humans?
Wilmut. The suggestion would be that it applies to mammals. There’s a predic-
tion that the level of mortality in a particular species will be related to the bio-
logical costs of losing that foetus, and in humans, we’re going to keep on trying 
anyway, no limit. So we can tolerate [prenatal mortality] in that sense – it’s sad for 
people who can’t conceive, I don’t wish to treat it lightly and apologise if I cause 
offence – but it might seem predictable that we have a very high prenatal mortal-
ity. Species at the other end of the curve, like bison or seals, where they only get 
one shot – possibly one mating, certainly one reproductive cycle – the cost of 
losing that foetus would be very high, and the survival is higher. And rats, mice, 
sort of fit in the middle of that. 
Alan Archibald. And pandas [laughter]?
Wilmut. What happened to me, I wasn’t party to the original discussions which 
decided that the new molecular biology projects in the Institute were going to 
involve embryo manipulation, but the then director [Roger Land] approached 
me and essentially said that I was going to provide that expertise of recovering 
and transferring the embryos. I can’t explain to you how angry I was [laughter]. I 
was one of the few PIs who was going to survive [the cuts at ABRO], a lot of the 
PIs were going to go, and I believe I owe that to Anne McLaren,8 for which I’m 
eternally grateful. So I’d had a reasonable personal track record and was being 
told what to do. I was very angry.
García-Sancho.  And this embryo transfer technique to surrogate mothers, did 
it receive commercial interest at the time?
3Wilmut. The technique itself was nothing new, and it was probably started in 
a number of labs in the late 1940s and 1950s. Certainly the Cambridge [Animal 
Research Station] lab where I did my PhD had been involved; South Africa, New 
Zealand, Australia and the States, it would’ve been several labs around the world 
who developed this. So there was nothing innovative that we did in the proce-
dure, but there was a company established here in Edinburgh, which offered the 
service of embryo transfer to farms. They did change the procedure. Ours was an 
intrusive surgical procedure, we just opened the abdomen, got the reproductive 
tract out. The commercial group used laparoscopy as a way of getting in.
Archibald. The commercial group were doing cattle, weren’t they?
Wilmut. No, they were doing sheep as well. 
García-Sancho.  And what about Rick Lathe and John Clark, the molecular bi-
ologists with whom Ian Wilmut started collaborating in the mid-1980s? What 
were they doing before joining the pharming programme?
Archibald. Rick [Lathe]’s background was with Transgéne in Strasbourg, and 
they were in essence a small biotech company. The projects Rick did back then, 
when he worked with Transgéne, included developing an oral vaccine against 
rabies.
Alan Colman. They were dropping chicken heads [with the vaccine] from planes 
and helicopters over in rural France, trying to immunise the wild animals that 
might be carrying rabies.
Archibald. And John Clark, when he did his work in John Bishop’s lab as a post-
doc, arguably, wasn’t doing genetic manipulation at all, he was looking at the 
expression of mouse [major] urinary proteins. And so the point of moving on to 
making transgenic mice wasn’t until they established the lab at ABRO, and the 
plan was that they were going to make modified cells to test the constructs, then 
make modified mice to test the constructs further, and then make the sheep. And 
we made the sheep before we had success in mice, if I remember correctly.
Colman. It’s hard to know if what you’re going to say is in or out of the imme-
diate context, but it follows on from what Ian was saying, if I could just give the 
history of PPL coming to Roslin, as it sets the context for the type of relationship 
we had. I’d been an academic, I’d done my PhD with John Gurdon,9 and one of 
the things I did as an academic was to inject messenger RNA into frog eggs. I was 
making mammalian interferon from frog eggs, and someone said ‘well, why don’t 
you start a company with you injecting frog eggs with interferon RNA?’ and this 
obviously wasn’t a feasible proposition, but that seeded in me the idea of going 
to chicken eggs, and you [Robin Lovell-Badge], I think, shortly after this wrote 
a little piece in Nature about pharming in chicken eggs, that is, making foreign 
proteins in chicken eggs – I think it was chickens?
Lovell-Badge. No, the first transgenic farm animals were being published, in 
Nature, by Ralph Brinster and people, and I was asked to write a ‘News and Views’ 
on that, on the first transgenic sheep, pigs and rabbits.10 
Colman. Well, the fact was we thought eggs would be a good proposition be-
cause laid eggs present a sterile environment. We were worried about the use of 
farm animals for the same purpose because of, you know, the dirty conditions 
they live under. At the time I was consulting for Prudential, an insurance com-
pany, earning a little bit of pin money, and we were looking for somewhere and 
someone who could do the work. One way or another, this search led us up to 
Roslin and Helen Sang. We set up a project where I was a sort of project monitor, 
to make transgenic chickens, and it was by that contact with the Roslin Insti-
tute, though it wasn’t called that at the time, that I became aware of Clark’s and 
your [Ian Wilmut’s] work on the production of human proteins in the milk of 
transgenic sheep. I had no idea about this work when we started the transgenic 
Laparoscopy (‘keyhole surgery’) 
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formed through a small inci-
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response to a virus, which 
has the property of inhibiting 
virus replication. It is used as 
a pharmaceutical.
4chicken project. As a result of this realisation, we (myself and Prudential) decided 
to sponsor work on the farm animals, and ultimately, a company was started. 
There were problems with starting a company at that time with a government-
run institute because although nowadays what would happen is that the Insti-
tute would start the company, then it was expected that outsiders would fund 
it. I recollect that government rules prevented that type of initiative, so you guys 
couldn’t start your own company, so we licensed the technology and started a 
company. The company subsequently became known as PPL but originally it was 
known as Caledonian Transgenics, a very parochial name. That’s where our in-
volvement in the pharming started. 
Now to return to the subject of making proteins in the milk of transgenic 
animals, we wanted, ultimately, a more reliable way of making transgenic farm 
animals because the method of DNA microinjection of fertilised embryos, which 
you, Mr Chairman [Robin Lovell-Badge], summarised in your ‘News and Views’ 
article, was very inefficient, with only three to five percent of the animals born 
to the microinjection technique being transgenic. In mice, it was possible to use 
genetically-manipulated embryonic stem cells to make transgenic mice. Many 
groups including ours at PPL were looking for farm animal embryonic stem cells 
for the same purpose, so we were looking round the world for sources of such 
embryonic stem cells. Our search failed and it was really when we heard of, I 
think it was Jim McWhir and Ian [Wilmut]’s nuclear transfer work, that we were 
alerted to possibly a new way of thinking about making transgenic animals, and 
also making precise changes in the genome as had been done in mice. 
Archibald. Going back to the pharming, of course the whole idea of trying to 
make valuable therapeutic proteins in farm mammals, or animals, went back to 
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5the first efforts in terms of moving up to genetic modification at what was then 
IAPGR. When Rick Lathe11 came on board as head of molecular biology, we tout-
ed around the idea, round the big pharmaceutical companies, we touted it to the 
British Technology Group, all of them were saying, ‘This isn’t going to fly, this 
isn’t going to work.’ Where arguably Rick and John Bishop12 started from was 
the closing paragraph of Brinster and Palmiter’s paper on transgenic mouse13 – 
the giant mouse – which said, ‘it has not escaped our notice that these animals 
have got huge levels of circulating growth hormone’, and so of course the USDA 
[United States Department of Agriculture] Beltsville laboratory went along the 
route of trying to produce transgenic pigs, and after looking at other bits of the 
second Brinster and Palmiter paper14 – and by the way these animals have got 
arthritis, this, that, the next thing, and fertility problems – we picked up on the 
almost throw away remark, the high levels of growth hormone, and we said, why 
don’t we try making something more interesting than growth hormone, and do 
it in sheep?
Lovell-Badge. So then the first products that you tried to make were  … Alpha-1-
antitripsin was one, but there were several.
Colman. Correct, we were quite lucky in that the first sheep we ever made in 
the collaboration with Roslin, called Tracy the Transgenic [born in 1990], made 
an extraordinary amount of human alpha-1-antitrypsin in her milk, which caught 
the attention of many people when it was published in Nature Biotechnology 
(Fig. 5).15 The company attracted a lot of inward funding from that point, because 
of that one demonstration.
Lovell-Badge. I think there were attempts to make mice with the alpha-1-an-
titrypsin expressed in the milk, but the mice we made in London using just the 
human gene with its own regulatory sequences were making more.16
Archibald. Well, the alpha-1-antitrypsin construct that PPL injected produced 
Tracy.
Lovell-Badge. That was tried in mice first, though.
Bruce Whitelaw. Yes, it was.
Archibald. Yes, they put that into mice, so that was the beta-lactoglobulin pro-
moter sequence that John [Clark] had isolated. We cloned the beta-lactoglobulin 
gene from sheep, and the alpha-1-antitrypsin one was the genomic construct that 
I’d got from Gavin Kelsey, because I’d been in some meeting in London where 
Gavin had described his work with putting that into mice.
Lovell-Badge. It was the human gene?
Archibald. Yes, and the human alpha-1-antitrypsin promoter, and that worked 
very well as far as I can remember. Okay, this is a simple cut and paste job, and 
it was.
Schnieke. It works very poorly with the cDNA.
Archibald. Yes, we had a whole string of constructs.
Whitelaw. We made a series of constructs, we called them A, B, C and D. It was 
B that you ran with, the one Alan’s talking about. We made various versions of the 
C and A ones carrying alpha-1 or Factor IX, and we put them into mice, and most 
of those were poor, to say the very least.
Colman. Do you remember where you got it from?
Whitelaw. It was from Gavin Kelsey, we got the alpha-1 from Gavin Kelsey. 
Colman. And where did he get it from?
Whitelaw. He cloned it, did he not clone it?
Lovell-Badge. He was in Sue Povey’s lab, she had it.
Colman. Where did she get it from?
Lovell-Badge. They cloned it [laughter]!
Archibald. I remember, for comparative purposes I got hold of some of Gavin’s 
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6mice. I must’ve been in London and I brought them back to Edinburgh on the 
train, and it’d been a long series of meetings I’d had in London, so I was really 
tired and I kept falling asleep and having nightmares about the train derailing 
and these mice escaping [laughter].
Harry Griffin. It might be useful just to reprise exactly how Tracy was made.
Colman. Okay, this involved a microinjection of a human gene into a fertilised 
egg, into one of the two pronuclei. The human gene was linked at the DNA level to 
a sheep milk protein promoter called beta-lactoglobulin which had been isolated 
by Clark, and this was the driver if you like, the gene switch which made the hu-
man protein production almost exclusively in the mammary gland and therefore 
it went into the milk. We’d hoped, as had they [IAPGR scientists in Edinburgh], 
that ethically this approach would find some favour with the movements that 
were set against the use of animals in research – and of course, Roslin was a tar-
get for the animal liberation movement, and there had been an arson attack at 
some earlier date.17 As a result of public concerns, when Tracy and animals like 
Tracy were made, we were told by the government to make sure that psychologi-
cally these animals were alright. We had already established that physically the 
animals were unaffected by the transgene. Subsequently, a paper was published 
describing 20 transgenic sheep and 20 related siblings that didn’t have the gene, 
sitting in a field, and their behaviour over a six week period was noted by animal 
psychologists, with the conclusion that the transgenic sheep were no different in 
behaviour.18 As I say there was a lot of attention, a lot of concern about transgen-
esis in large animals in case it created monsters and all those sort of things. So we 
were always treading a line, as a company, worried about the public acceptability 
of what we were doing.
Lovell-Badge. So, was the idea of making proteins like alpha-1-antitrypsin driv-
en by being able to make large amounts of protein at a relatively low cost?
Colman. Yes, we were trying to meet an unmet clinical need. This particular 
protein is needed by congenital emphysema sufferers and they need infusions of 
four grams a week. They get the material at the moment (and at that time) from 
blood supplies, but there wasn’t enough blood available to satisfy the needs of all 
the sufferers.
Lovell-Badge. It was also not so long after HIV/AIDS and the whole idea of 
contaminated blood products. That was in the mid 80s, people were looking at 
ways of making clotting factors and other valuable proteins that you could only 
get from [blood].
Archibald. The two proteins we had, if you like, in the portfolio initially were 
Factor IX, a blood-clotting one, where the issue with producing that, using bio-
technology rather than isolating from blood, was the complex post-translational 
modification. With alpha-1-antitrypsin, it was the volume issue, in either animal 
cells, or trying to produce it in bacteria or yeast. You could not, if you had har-
vested all the blood products of the blood transfusion service, have enough to 
treat people with emphysema. Whereas with Factor IX, it’s modest amounts and 
a relatively small population to treat, alpha-1-antitrypsin was much more chal-
lenging in terms of trying to meet that market, well market is not really the right 
word for it …
Lovell-Badge. Does anyone want to add on to this? So the whole concept of 
pharming, were there several places around the world doing it?
Colman. Yes, as I said, we thought we had a lead in this area when we began the 
transgenic egg project, but truthfully it was very difficult to make transgenic eggs, 
terribly difficult.
Sang. Yes, we didn’t really have the technology, because manipulating a hen’s 
egg is much different from manipulating a sheep egg, and so it took us too long 
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7to get to the point where we could actually start making proteins in eggs. And 
the work on milk and sheep took off, and I think working with sheep, part of that 
was that sheep were much cheaper, is that correct? Rather than working in cows, 
for example?
Wilmut. I think it was more practical at the stage of producing the animals, 
actually handling the animals and recovering the embryos for transfer – plus we 
had the experience with sheep. And it was very likely that if we made something 
work in sheep it would also work in cows, which is true, so you could just apply a 
proven method in cattle.
Archibald. And of course, the company that succeeded at the end of the day at 
getting a product into use [GTC Biotherapeutics], as far as I recall, produced it 
in goats.19 Cattle are obviously a damn sight more expensive, you’re dealing with 
100s of eggs in order to get a successful one.
Colman. I think another company got milk products approved for sale, human 
milk products out of rabbit milk. The company was called Pharming, in Holland, 
and it was our biggest competitor at the time. They also made Herman the Bull.20 
John Bracken. A question for Alan [Colman]. You were so successful with Tracy 
and the amount of milk she produced with the human protein. Did you ever re-
peat that to the same degree, or was that the best you ever managed to achieve in 
the production of protein?
Colman. No, for the alpha-1-antitrypsin she was the best ever, but we subse-
quently made a sheep expressing in its milk 70 g/litre BSSL [Bile Salt Stimu-
lated Lipase, a breast milk enzyme involved in fatty acid metabolism]. We had 
licensed the gene from a group in Sweden, however, no further development of 
this project occurred.
Sang. You couldn’t milk them [laughter].
Bracken. Was that microinjection again?
Colman. That was microinjection, yes … So it could be a wonderful technology. 
I mean, it turned out that goats were probably a better choice as a medium-size 
animal, because the average milk-yield of a goat is a lot better than that from 
sheep, but there you go.
Bill Ritchie. I think that you’ve got to remember that at that time all the oocytes, 
the embryos, were actually recovered by surgical methods, so that made it much 
more difficult for you to actually use something like cattle. Probably sheep were 
the best animal to use for any of these experiments.
Wilmut. I think that’s a good point, I mean, by now, with the proved technol-
ogies for in vitro maturation and fertilisation in embryo culture, you probably 
could make it work in cattle, it would be reasonably economical.
Colman. I think when we did cattle in the US and we used in vitro maturation 
from abattoir cow materials to get the eggs, we never used live donors at all, but 
that was some years after of course …
Ritchie. I think the technology developed, but when we started doing these 
experiments all the oocytes or embryos we were using were recovered by surgi-
cal means. That was a huge amount of work, and a huge amount of people were 
actually involved in it, because all these animals superovulated, so that involved 
farm staff as well, to actually superovulate these animals.
Lovell-Badge. Any specific questions? Miguel [García-Sancho], you did ask me, 
is pharming an appropriate term?
García-Sancho. Yes, one thing we were wondering is what word you used at the 
time to designate that line of research on genetically modifying animals for a par-
ticular purpose. I wasn’t sure if the word pharming arose after the actual genetic 
modification efforts at Roslin. How did you designate that research programme 
at the time, which term did you use?
Superovulation is a hormo-
nally-induced procedure that 
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8Lovell-Badge. The word pharming had come earlier, much earlier, it was being 
used in other systems too, in plants.21 
Jim McWhir. While it’s true that PPL’s interest was, I think exclusively, in bi-
opharming, we should point out that those of us at Roslin probably had a wider 
range of interests. We were interested in the possibility of making farm animal 
models of human disease, for example, and doing that using gene targeting tech-
nology. There were also those of us who were interested in being able to use a 
somatic cell intermediary so that we could assess levels of gene expression prior to 
going to the expense of making an animal. At that time I’d just got my first Medi-
cal Research Council grant, to engineer mouse embryonic stem cells and look at 
the possibility of deriving therapeutically relevant somatic stem cells in vitro, and 
we were interested in doing that ultimately in farm animals. Have I forgotten 
anything, Ian [Wilmut]?
Lovell-Badge. There were other areas of potential interest, so obviously disease 
resistance in farm animals. Still goes on today.
McWhir. And then, of course, reproductive cloning of elite animals, but I think 
that was probably of the least interest.
Wilmut. I don’t think anyone’s mentioned animals as donors of organs.
Angelika Schnieke. Within PPL we had two areas of interest. We had some 
projects where we wanted to replace the ovine or bovine gene with a human 
gene. I think we had two or three different projects, for which we needed the 
homologous recombination (i. e. gene targeting) technologies. We needed to have 
some types of cells, either embryonic stem cells, or some kind of substitute, 
where we could carry out homologous recombination. And then we also started 
in the area of xenotransplantation, and again, we needed to be able to manipulate 
endogenous genes, to be able to carry on in this area. At the time we worked a lot 
together with Jim in the area of stem cells and homologous recombination, and 
through him we also became involved in the whole Dolly project.
García-Sancho. You have also mentioned a very interesting collaboration be-
tween Alan Colman and Helen Sang, making transgenic eggs. There was another 
important line of research at what was then the Poultry Research Centre on mak-
ing transgenic chickens. I was wondering whether you could discuss if there were 
connections between this programme and the one on sheep and any other ani-
mal you might have explored at the time.
Sang. If we go back even further in history, it was when molecular biology was 
really taking off in bioscience and in Edinburgh in particular, and at that time 
there were two institutes. There was the Animal Breeding Research Organisa-
tion [ABRO], which was at King’s Buildings [in South Edinburgh, next to] the 
University of Edinburgh [buildings] and the Poultry Research Centre that was 
in Roslin village. There were new appointments made, and people began to get 
involved in molecular biology at both sites, and then we were put together as part 
of the Institute of Animal Physiology and Genetics Research [IAPGR], and the 
people from ABRO were moved out to the Roslin site. We had this going on, ap-
plying molecular biology as a research tool in general, but also trying to develop 
methods for genetic modification in chickens, at the Poultry Research Centre, 
and in farm animal species at ABRO. And then we all were merged together and I 
would say, we had a slightly uncomfortable relationship, really. Bringing the two 
institutes together wasn’t particularly smooth.
Lovell-Badge. In what context [did you attempt to apply molecular biology] 
other than mammals and chickens?
Sang. I think it took a while, and certainly I used to go to meetings with Gra-
hame Bulfield, and Clark, and Lathe, and Paul Simons, and – I don’t think you 
were at those, Alan [Archibald]? 
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9Archibald. I’ll tell you in a minute.
Lovell-Badge. But was it also in the context of a 
general, more quantitative genetics of traits [in ani-
mals]?
Sang. The Poultry Research Centre had very little 
[quantitative genetics], and the real quantitative ge-
netics was a strength of ABRO, and that’s an ongoing 
strength at the Roslin Institute
Griffin. Your major challenge in manipulation was 
that by the time the embryo was accessible, it was 
10,000 or 20,000 cells
Sang. 60,000, yeah.
García-Sancho. Alan Archibald, were you also involved in these meetings?
Archibald. I’ve spent my entire life in meetings since 1981. The merger of ABRO 
and the Poultry Research Centre was kind of the next phase after the Thatcher 
government tried to effectively close it [ABRO], and so moving into molecular bi-
ology and into the kind of work Ian [Wilmut] was already involved in. But under 
Roger Land’s leadership we possibly took a greater emphasis in terms of what we 
were doing, in assisted reproductive technologies, plus moving into molecular 
biology. And there were two possibilities in molecular biology. One was to get 
into what in essence was the foothills of genomics research, which was my own 
particular interest, but Roger was putting more emphasis on genetic modifica-
tion, which is, in essence, where the pharm[ing] project grew out of. It was that 
particular idea that you should use molecular biology to change animals, rather 
than to try and work out what genes are controlling the traits. We were running 
those two strands in parallel, and the genomics bit took off five years later.
Wilmut. Yes, reproductive manipulation techniques were going on under John 
King,22 that’s the reason, in a sense, why I was recruited to ABRO [in 1973], to 
bring in those sort of technologies, not for the purpose that they were actually 
used for, but more for use in the Hereford context.23 
Archibald. So there was a kind of coming together of the assisted reproductive 
technologies and quantitative genetics with the sort of thing Charlie Smith was 
doing in terms of multiple ovulation embryo transfers.24
Wilmut. That was the objective. It never really happened, I think, because the 
facilities which were ultimately made available took a long time to come, we were 
doing other things.
Sang. I think it is important to know that there were these different streams 
of activity going on with very different expertise, and that’s what was pulled to-
gether in bringing the whole transgenics and then cloning. 
2. Dolly and her flock
Lovell-Badge. The next topic I was going to raise is the relationship between Dol-
ly and the sheep that preceded and succeeded her. My little list seems to include 
Tracy (we’ve talked about her already), Morag and Megan, Dolly, Holly, Ollie, 
Molly, Polly, and then Cupid and Diana. So, no Folly?
Colman. And no Bolly. They stated that PPL were going to make lots of money, 
so there should be a sheep called Bolly, after a well-known champagne [Bollinger]. 
And the name Trolley was suggested from the saying ‘they’re off their trolley’ for 
doing this sort of thing – so lots of humour in the press!
Lovell-Badge. Obviously, Morag and Megan were the first cloned sheep (Fig. 6).
Wilmut. Yes, once we got the project started, the key to it was Keith [Campbell], 
really, who investigated what happened after you did nuclear transfer, how to 
optimise the process. He did a PhD in Sussex. 
They stated that PPL were  
going to make lots of money, 
so there should be a sheep 
called Bolly, after a well-
known champagne 
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Sang. With Chris Ford, I think.
Colman. There were frogs involved in some of the work he did.
Wilmut. He was looking for MPF [maturation promoting factor], looking to purify 
and identify the components of MPF. It was not surprising in a way that if he was 
working on his own he didn’t make much progress, but in order to make progress 
with the cloning, we needed to know about that activity, so as somebody who had 
thought a lot about the role of these proteins in cell cycle, knew one or two key 
assays to follow the activities, he was perfectly placed to analyse this. 
Lovell-Badge. So, what was the reason for going for oocytes rather than fertilised 
eggs, which had been tried in the mouse?
Wilmut. There were one or two people doing mouse work who were beginning 
to use oocytes, people in Japan. I can’t remember how this would’ve fitted in with 
what we did, but you’d fairly quickly have had subjective assessments that oocytes 
were giving you better reprogramming. But they wouldn’t have a high level of 
MPF activity, I don’t know the answer as to why they didn’t. I guess it could have 
been because when we started using oocytes we wouldn’t have had the profile of 
MPF activity, it would have taken a few months of research activity to do that.
Lovell-Badge. And then there were various tricks employed like blocking mitosis?
Wilmut. Yeah, there’s a limit to how long you can hold cells before you poison 
them, and it’s probably not a very accurate process. The cells of the early embryo 
don’t have the normal checkpoints, so it’s actually biologically not easy to stop 
them. So, really, if you’re going to use cells from early embryos you’d do much 
better to pre-activate the oocytes and then just transfer a donor nucleus in, at any 
stage of the cell cycle – you know, it’s practical. That’s what we did with the sheep 
that I suspect Megan and Morag came from.
McWhir. They came from the TNT [totipotent for nuclear transfer] cells, which 
was the cell line that we isolated.
Wilmut. Yes, I remember that, but I think Keith [Campbell] checked and showed 
that they would stop [the developmental cycle], and also start again.
Lovell-Badge. Why was that particular cell line chosen?
Wilmut. Jim [McWhir] had been trying for a number of years to get stem cell 
lines going out, and the way I remember the description is that you didn’t get a 
massive, bulging out of a different cell type, the ones we were interested in sort of 
simply disappeared. Would you say that’s a naïve but fair description?
McWhir. We had isolated something, which probably technically wasn’t a cell 
line, it depends on how you define a cell line, and if you define a cell line as some-
thing that’s adapted to perpetual culture, it wasn’t, but we could keep these cells 
going for 15 or 20 passages, which was probably enough to do genetic modifica-
tion. So although we had no evidence that they had the properties of embryonic 
stem cells, they did have some of the properties of cells that we could genetically 
modify, and so they were interesting candidates for nuclear transfer for that rea-
son.
Wilmut. The idea of that experiment was to do nuclear transfer from this pop-
ulation, to see whether the ability to support development stayed the same or 
whether it decayed and, if so, over what time period.
Colman. Could I just clarify, because this is new to me, so the nuclear transfer 
was secondary, it was just a test of the totipotency of those nuclei?
Wilmut. Yes, and it didn’t come out very cleanly, that’s the problem. It did drop 
[the cell’s developmental capacity], but it was sort of a dithering line.
McWhir. I think probably different people have slightly different interests for 
obvious reasons, so correct me if I’m wrong, Ian, but I think you were interested 
in evaluating the differences between the behaviour of cells of different origins 
in nuclear transfer. And I was primarily interested in the possibility that the TNT 
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cells might be useful for doing the kinds of things that we wanted to do down the 
line, so Ian’s interest was possibly slightly more basic than mine, mine was a bit 
more utilitarian. Would that be a fair summation?
Wilmut. Yes.
Schnieke. I think that was also the point where PPL became interested. I can re-
member we once sat together at lunch: Alex Kind, who was doing cell culture and 
stem cell work at PPL, you [Jim McWhir] and I. This was the time of the Megan 
and Morag pregnancies, I think it was still early pregnancies, and Jim was telling 
us about his cells, that he can culture them for a while, and that they had given 
rise to these pregnancies. And that’s when we discussed that this could also be of 
interest for PPL because we wanted to carry out genetic manipulation. If we had 
cells in culture that we could manipulate, and if they could then give rise to preg-
nancies this would be an ideal project. That’s when you [Jim McWhir] suggested 
maybe I do a PhD, and I went to Alan [Colman] and asked for financial support 
for this [laughter], and that’s when the next part of the project started, when the 
next animals were generated. 
McWhir. Well, I think that illustrates the value of this exercise because I had 
actually forgotten that, but I now remember it.
Schnieke. It was in the canteen at the Roslin Institute where we were sitting at 
lunchtime – best meetings ever.
Colman. But Megan and Morag is really the most important of the publications, 
not the Dolly one, which was where the technology was further validated.
Ritchie. That’s what Keith [Campbell] would always say: that was the most im-
portant experiment, Morag and Megan, and Dolly was a consequence but not the 
real breakthrough.
fIGuRe 6. Megan and Morag, 
born at Roslin in 1995, were 
the first sheep cloned from 
cultured embryonic cells.  
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Wilmut. There’s been an awful lot of discussion 
about the authorship of these papers.25 I’m interested 
to hear you say what you’ve just said. I was going to 
be the first author of the Megan and Morag paper, 
but because he [Campbell] put the G ₀ component in, I 
suggested he should have it and I would have the next 
one, and that’s why I ended up with Dolly [ laughter ].
Sang. Maybe Harry [Griffin] can remember – Meg-
an and Morag’s was a paper in Nature, wasn’t it? And 
there was a lot of interest, which hadn’t really been 
anticipated, so when the Dolly paper was coming 
along, Harry in particular sort of made sure that peo-
ple were ready in case there was interest, but there was still the feeling that maybe 
it wasn’t as significant as Megan and Morag.
Griffin. I think the media interest for Megan and Morag lasted about seven 
days, so there was interest, but nothing like when Dolly was born, or at least an-
nounced.
Bruce Whitelaw. There was an unfortunate reason for that cut-off of interest – 
Dunblane [school massacre].26 
Colman. Is that right?
Whitelaw. Dunblane happened about six days after we announced [Megan and 
Morag]. But even with that, the interest was in a different league when it came 
to Dolly.
Griffin. Maybe it’s appropriate, given we’re discussing the timeframe here. 
When was the patent taken out? 
Wilmut. 1995
Griffin. And what did it cover?
Wilmut. Everything we could think of.
Griffin. Because it was taken out after Megan and Morag were born.
Colman. Yes, but before [the research] was published. We poured over the pat-
ent. There was one unfortunate aspect of the patent specification. It insisted, I 
think, that the use of G ₀ cells to provide nuclei was the secret to success, and 
people at the time (although we challenged it successfully later) argued that if 
you used another stage of the cell cycle other than G ₀, it wasn’t conflicting with 
this patent. We suggested that the patent should have used the term ‘preferably 
G ₀.’ The use of ‘preferably’ is a common patenting device to improve the breadth 
of the patent claims.
Wilmut. Even preferably is a bit strong. It would have been better still if it had 
been, in laymen’s English it would be awaiting DNA replication, for example, in 
G ₁ or G ₀.
Lovell-Badge. And was the patent taken out by Roslin?
Colman. Oh yes, they made the technology available for licensing.
Lovell-Badge. So there was some media interest. I remember a little bit myself, 
but it wasn’t huge amounts.
Griffin. No, I wasn’t involved in handling that, probably, Ian, you were.
Lovell-Badge. But there was a lot of scientific interest, I’m assuming. Because 
they would’ve been the first mammal clones.
Wilmut. First from a cultured cell line was, I think, how we described it.
Schnieke. But I think the emphasis was probably still slightly different in the 
publication, it wasn’t so much that it was a differentiated cell, it was proposing 
that it might be a stem cell.
Lovell-Badge. Embryonic, yes.
Schnieke. Yes.
That’s what Keith [Campbell] 
would always say: that was the 
most important experiment, 
Morag and Megan, and Dolly 
was a consequence but not the 
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Lovell-Badge. I remember there was a lot of discus-
sion about whether it was still embryonic or not.
Colman. And I think I’m right in saying that you 
and Keith were quite concerned after the publica-
tion, because there’d been a lot of losses, in pregnan-
cy and everything, and you were worried about the 
knock on effect of making unhealthy animals, and 
things like that. Quite concerned, weren’t you?
Wilmut. It was when the effects on birth weight 
first became apparent as well. 
McWhir. Can I return briefly to the question of 
which was the more important paper [ laughter ]? Be-
cause I think I have a slightly different perspective, 
although I had more involvement in the Morag and 
Megan paper, so it would be very congenial to me to 
think it was important. But my view of the history of 
the cloning technology is that previously, there was 
a received wisdom that cloning worked for very early pre-implantation embryo-
derived cells, and as you took those cells from progressively later developmental 
stages, the efficiency rapidly plummeted and was effectively zero after the blas-
tocyst stage. And so, the conventional wisdom was that there was an irrevers-
ible differentiational commitment, and that’s why so many people disbelieved, 
initially, the Dolly result. So in my mind, when the Morag and Megan paper came 
out, possibly because I didn’t have the insight that Ian and Keith had into the 
techniques that had been used in developing the cloning, in my mind it was still 
very much up in the air, whether or not that success was a property of the cell of 
the embryo-derived cell line, or whether it was a consequence of the modifica-
tions that Keith and Ian had introduced into the techniques. So the way I think of 
this is that the Dolly paper showed unequivocally that there was nothing special 
about the TNT cells, and that you could take probably any differentiated cell and 
completely reprogramme it. Convince me I’m wrong, but I would say that the 
Dolly paper was more important. 
Wilmut. Can I ask a nasty question? Did Shinya Yamanaka or anybody else rush 
off to produce iPS cells after Megan and Morag?
Colman. No, I think people were inspired by the Dolly experiment. I think what 
I was referring to was the technical tour de force, which was in the first paper, and 
the second paper just used the same technology, but you have a point.
Schnieke. It proved a dogma.
Ritchie. Yeah, I think that’s right, in that the techniques that were used, in the 
actual cloning itself, were so much different to what had gone before. [With our 
technique] you had the potential of genetically modifying those [cells], whereas 
you didn’t have that in the previous technique [used by Willadsen], where you 
were taking an embryo which has 16 cells. 
Lovell-Badge. Also, in terms of frog experiments, you could clone from a larval 
stage of a frog, but you couldn’t do it from an adult.
Colman. That’s correct, and you still can’t. As we’ll discuss later, when we were 
discussing the idea of putting [adult] mammary cells in, which was late in the day, 
I didn’t really feel it would work at all because of the John Gurdon experiments.
Schnieke. Exactly.
Colman. I just didn’t think it would work and some of the others didn’t think 
it would work. Some people didn’t say anything but I think no one absolutely 
thought it would work.
Wilmut. Keith [Campbell], probably.
Dolly […] showed unequivo-
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Colman. I don’t think so … I spoke to Keith, he didn’t, he was neutral.
Schnieke. I think it took a long time convincing Alan [Colman] to support the 
project using the cells that then gave rise to Dolly.
Wilmut. You [Alan Colman] made a wager. Do you remember making a wager? 
Said you’d eat your hat [ laughter ]. He hasn’t, but we could provide one, I’m sure.
Schnieke. I think you also made a comment to me, ‘it probably won’t work.’ And 
I think we were very lucky.
Colman. Well, when we come to talk about the experiments that led to Dolly, 
it’ll be very interesting to hear what was going through the thought processes of 
the Roslin people, because this collaboration was an example of a commercial 
organisation interacting with an academic [institution], where the commercial 
organisation, because the academic did a lot of the technical work, had to share 
with them exactly what they were using. In contrast, there was a part of the Dolly 
series of experiments which we never knew about until there were births. We 
never knew about the use of foetal fibroblasts, so the secrecy was rather one-sided 
here but that was the way it was.
Lovell-Badge. What happened to Megan and Morag?
Wilmut. They’re in a museum, The National [Museum of Scotland]. 
Ritchie. Only one of them is. 
Wilmut. Which one?
Colman. Megan.
Wilmut. Yeah, you’re right, because the other one lived for a much longer time, 
didn’t she?
Ritchie. Yeah, she did.
Lovell-Badge. What’s the reason?
Ritchie. Well, the other one lived for fourteen years.
Wilmut. Really?
Ritchie. It was put down because of extreme old age. It became a pensioner.
Lovell-Badge. So then, Dolly. Let’s explore what you were talking about, the 
choice of cell lines.
Colman. I think we can all contribute to this. The collective memories might 
be different and it’ll be interesting to see what we did. We wanted to follow on 
from the work you were describing, Jim [McWhir], and make lines, embryonic-
derived lines, which were qualified so that they could be used in our own facility. 
We had a very clean facility, because at the end of the day, we were trying to make 
drugs for human use, we wanted to get some of our own embryonic cell lines and 
we wanted to validate them by nuclear transfer, and wanted to collaborate with 
Roslin, because they were the people who could do that. We couldn’t perform the 
technique by ourselves at that time. We made four – Angelika can correct me – 
four cell lines, different lines, and we wanted to use two thirds of the sheep that 
we’d communally bought – Roslin actually bought them and paid for them, but 
we had agreed to pay I think for two thirds of the overall project. We wanted to 
just validate the cell lines by getting live births from each of them. Had that oc-
curred, we’d have four different lines we could play with for genetic engineering. 
Because we were a commercial organisation we wanted to have a contract, and 
we wanted to be able to license the technology that Roslin had patented so that 
we could use it in the future. We wanted two types of licences: one for making 
proteins in milk, which is where we already had expertise, and also organ trans-
plantation, to use the technology to knock out genes and modify pig organs, in 
fact. We hit a block there, because Roslin, probably rightly, didn’t want to license 
the xenotransplantation uses to us [PPL] because we had no track record at all 
in this area, so they wanted to license it to an organisation that might be better 
placed to take advantage [of the patents], so they didn’t want to give us a licence 
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for that. There were interminable negotiations going on, and meanwhile, the 
sheep season – because these animals are seasonal breeders – was going to close, 
and that would mean if we did these experiments together we’d have to wait 
another year to actually get started. Neither side wanted to do that, so I made 
the decision to go ahead with this project, even though we didn’t have a signed 
contract or licence. We just had a gentleman’s honour agreement, and I have to 
say that, at the end of the day, Roslin completely honoured that, but at the time 
we didn’t have a contract. 
We set up a project management group of myself, Angelika, Alex Kind from 
PPL and I think it was Jim [McWhir], Keith [Campbell] and Ian [Wilmut] from 
Roslin. We’d have monthly meetings, I think – I can’t remember the exact fre-
quency of the meetings – just to monitor progress, and I think what happened 
was that two of our four lines, I think it was two, fell by the wayside. They were 
karyotypically abnormal, therefore you would never contemplate using them for 
nuclear transfer, and we didn’t have any other lines available, embryonic [lines]. 
And I think that’s when Angelika piped up, ‘Well, we’ve got this mammary cell 
line which we’ve had frozen for two years,’ and we developed that mammary cell 
line to do what you mentioned earlier, we wanted a quick assay for transgenic 
constructs to see if they were going to go [work] in sheep. The idea was you put 
the [DNA] construct into a mammary gland cell in culture and see how much 
milk protein it produces. Then you can refine your construct and introduce it, 
by the conventional microinjection procedure, into an animal. But the problem 
was, when you take these mammary cells into culture, they dedifferentiate very 
rapidly and they are pretty useless as mammary cells, so we just froze them away 
but you [Angelika Schnieke] had karyotyped them and shown them …
Schnieke. I remember it was in the early days when Alex [Kind] was still work-
ing on the mammary cells, that we had the idea that if you could actually differ-
entiate them, use them to test your transgene of choice and show that the trans-
genes are expressed, that you could then use the same cells to make the sheep via 
nuclear transfer. That’s when we first suggested the idea, but it was seen as much 
too risky. We carried on trying to isolate the embryonic cells, and then we had a 
problem, like you said, I think one or two isolates got contaminated and fell by 
the wayside, and we spoke then again that maybe now we should try out these 
mammary cells. If the whole project would work we could actually do a readout 
and then produce the animal. In the end, we got the animal, the readout didn’t 
work [ laughter ].
Colman. Yeah, because of my own background working with John Gurdon, I 
knew a lot about frog nuclear transfer, and I didn’t think it would work, but we 
didn’t have any other validated cell lines and we had all these sheep that had been 
purchased, so we went ahead.
Griffin. And by chance those cells came from another animal research institute.
Schnieke. That’s right, it was in collaboration with the Hannah Institute.
Griffin. Which was quite useful, a little later on.
Colman. It was, yes, when we were challenged.
Schnieke. And the cells were from an old sheep, and that also made it very in-
teresting to see if those cells could still go through the nuclear transfer.
Ritchie. I think we were very lucky to actually get animals from these cells at all, 
because we did the experiments the last two or three weeks of the sheep breeding 
season, and we actually increased our nuclear transfer days. We used to do two a 
week, and we actually increased these to three days a week so we actually did it.
Sang. So were the cells from an adult female? 
Colman. Yes, six years old.
Sang. Six years old? Wow. 
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Colman. We were totally unaware that Keith [Campbell] and Ian [Wilmut] were 
using foetal fibroblasts in their part of the project.
Wilmut. That surprises me, I must say.
Colman. Yeah, we just didn’t know.
Schnieke. I mean, you can probably confirm it, Keith would not say what ex-
actly he was doing [ laughter ]. Would not want us to know how he treated the 
cells. The different cells which we isolated, whether it was the embryonic cells or 
the mammary cells, we had to hand them over to him for his final treatment, and 
he would not allow us to know what this was.
McWhir. Well I feel very honoured, then, because he told me [ laughter ].
Colman. But the irony was, of course, that the foetal fibroblasts were by far the 
most practically interesting cells that were being used in that whole programme, 
because there were huge numbers of them and they didn’t have quite the prob-
lems of the embryonic cells in terms of longevity and robustness.
McWhir. You might have had cloning issues though … They might not have 
behaved so amiably if you tried to single-cell clone them.
Colman. Oh, but we went on to use them exclusively to do the genetic manipu-
lation experiments that concluded in Diana [a sheep]. So, they worked very well.
Wilmut. Can I give you what you would recognise as the developmental biolo-
gist’s thinking, as the way in which Keith and I viewed the Dolly experiment? I 
mean, having got the offspring from the embryonic cells in the procedure that 
we were beginning to have some confidence in [Megan and Morag], clearly our 
next objective had to be to use foetal cells and adult cells. The problem was, we 
knew how many we had to make, had to reconstruct. That was 200 embryos in 
order to have a chance of having a realistic assessment of the technology, and if 
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we wanted to compare two, we each had to have 200, so we simply couldn’t af-
ford enough sheep to do the two treatments in one year. I don’t know whether 
we would have been able to squeeze the work in – possibly. What we set out to 
do was for us to do the foetal cells, as has been mentioned several times, and be 
prepared and able to take the additional embryo-derived cells and test. I guess it 
must have been about half way through the season, when we would’ve seen the 
foetuses by ultrasound from the foetal cell line, and perhaps, you know, one good 
line. We were learning from you [Alan Colman] that you’d only got one line to 
test and therefore you had sheep to spare, so that’s the context in which it became 
possible to do the adult line in the same season.
Schnieke. No, we had done the number of embryo transfers for those embry-
onic lines, as had been planned, and instead of another embryonic line, which we 
didn’t have because of the contamination problem, we then used the adult cells. 
So the fixed sets of experiments, which we were supposed to do, were done.
Griffin. I remember an institute meeting where Ian put a proposal, to squeeze 
in some extra sheep in that sheep season, and I think the cost was about £15,000, 
you must have been there, at that same meeting.
Archibald. I hadn’t reached the elevated heights of the management by that 
point.
Griffin. I’d contradict it [ laughter ].
Wilmut. So in that one season – I’m looking at the source of knowledge – in that 
Dolly season, were there lambs born from both embryo-derived …
Schnieke. All of them, all three! [foetal fibroblasts, embryo-derived and adult 
mammary cells].
Ritchie. There were actually seven sheep born in that year.
Lovell-Badge. So which sheep were those?
Ritchie. The three cell lines that were successful were embryonic, foetal and 
adult, so we got four from the embryonic, two from the foetal and one from the 
adult line. 
Lovell-Badge. And two of those were Morag and Megan?
Schnieke. No, the embryonic cells and the adult cells came from PPL, the foetal 
fibroblasts from Roslin, PPL paid for the experiments with the embryonic cells 
and the adult ones. For the foetal fibroblasts, Roslin did. 
Lovell-Badge. But the cell lines hadn’t been manipulated in those other sheep?
Colman. No.
Lovell-Badge. So they were, sort of, the proof of principle. 
Schnieke. That was the next thing to do.
Lovell-Badge. There are lots of figures we know about Dolly so there’s no point 
in reproducing those. But obviously Dolly generated a huge amount of publicity, 
are you saying that came as somewhat of a surprise, to some of you?
Griffin. No, I think you have to be in the centre of a media storm to know how 
intense it is, and Dolly was the tenth biggest news story in the world that year. 
Knowledge within the institute was kept to a very small number of people: right 
up to maybe two or three weeks before, I didn’t know anything about it.
Lovell-Badge. Before the publication?
Griffin. Before the publication. I don’t think it was ever discussed at any of the 
Institute committee meetings. Because of the experience of Megan and Morag, 
we started discussions with PPL and their PR company, De Facto. Ron [James, 
CEO of PPL] was the principal spokesperson for PPL and I think Alan [Colman] 
was in reserve. I was hoping to avoid any contact with the press and just ma-
noeuvre in the background. We had media training for the principals including 
Ian, and De Facto got themselves all organised, and the whole thing was being 
planned to coincide with publication on the Thursday. The preceding Friday, the 
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press release was put out, embargoed, and that prompted pressure from New 
Scientist to send a photographer to take a picture, because they didn’t want to be 
a week and a day behind the pace [being a weekly publication]. We were all geared 
up to start handling press on the Thursday, and Ian, you got a phone call on the 
preceding Saturday.
Wilmut. Almost midnight. Trying to think who phoned …
Griffin. Well, I remember I was watching a rugby league match on TV at about 
four o’clock in the afternoon and Ian phoned and said The Observer was going to 
break the story the next day. So on the Sunday, I went into Roslin to try to handle 
the inevitable press interest, half past nine on Sunday morning, after we had seen 
Dolly on the front page of The Observer. Ron James was at the south coast, he was 
diverted to Basingstoke where De Facto were based, and we just handled phone 
calls from then, for weeks and weeks and weeks. It was the most intense period. 
The staff didn’t know anything about it, until they saw it in The Observer, and 
some of them were pissed off with that. 
Lovell-Badge. None of the staff knew about Dolly either at that point?
Sang. The majority didn’t.
Lovell-Badge. I’m going to tell you something in a minute.
Archibald. I didn’t come onto the executive until 2000, but I knew, I think … 
Maybe I knew from my trade union, saying you’ve got to be ready for this.
Griffin. I wasn’t aware of that, but by nine o’clock on Monday morning the car 
park was full of satellite vans, NBC, CBS, ABC, BBC, ITV, everybody and their 
aunt. It was an incredibly intense period.
Wilmut. We had a staff meeting on Sunday morning, didn’t we?
Griffin. Yes, there was a staff meeting at quarter past nine, which some of you 
would’ve attended. I didn’t attend it since both Alan [Colman] and I got dragged 
into dealing with the media. We kept the number of people that were dealing 
with the press as small as possible so we could maintain a consistency of mes-
sage, which was absolutely essential, I think we could’ve been badly mauled if we 
hadn’t handled it as well as we did … There’s one particular instance, my secre-
tary Francis Frame was on the phone, and every time she put the phone down, 
it would ring again, and that was probably true initially of every secretary at the 
Institute. One time, I overheard her saying ‘Ah, sorry, Ian Wilmut can’t handle it, 
he’s got too many things, just give me your name. Harold Shapiro?’ He had just 
been appointed Bill Clinton’s Commissioner for Bioethics or whatever, and Bill 
Clinton had asked him to report on the ethical implications of Dolly. So I said 
‘No, no, don’t put the phone down on him!’ [laughter] We set up a meeting or at 
least a discussion over the phone with Ian but, yeah, it was a mad, mad time. 
Colman. I think it had leaked within scientific circles. The publication was sup-
posed to be February 27th, 1997, and I was at a meeting in Florida in January, and 
in the swimming pool someone swum up to me and said ‘We know what you’ve 
been up to’ [laughter].
Lovell-Badge. Well, I actually knew. I guess it was the autumn of 1996, because 
I was involved in running a course on embryology and transgenics in Hong Kong, 
and Keith Campbell had come and given a talk about it. He was supposed to be 
giving a talk about Megan and Morag, but at the end of the talk he told us all to 
keep it secret [laughter]. And it did remain secret.
Sang. Yes it did, I think most people in the institute didn’t know. There were 
some people hinting that there was something that we didn’t know, but we didn’t 
know [laughter].
Schnieke. That’s really surprising, because everybody at PPL was so excited 
when it happened.
Lovell-Badge. Alright, I guess we’ve gone off a little bit ahead of ourselves in 
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some respects, but, in terms of the other sheep that followed closely …
Wilmut. Holly would be next, wouldn’t she?
Lovell-Badge. That’s right, Holly and Olly
Schnieke. Yeah, the next step really was to prove that you can genetically mod-
ify them, and I remember going to Ian and asking if they were planning what to 
do next, otherwise we would like to do another experiment. I think there were 
still problems with the contract. We discussed if we don’t start the experiments 
now, trying to make the transgenics, we come into the season problem again, and 
you [Ian Wilmut] just finally said, okay, let’s do another round. So we prepared 
constructs for Factor IX in this case, made the transgenic lines, and then, at the 
right time in the [breeding] season, gave them to Ian, and it worked.
Lovell-Badge. So were those Holly and Olly?
Schnieke. Yeah, they were the Holly, Olly, Polly, Molly, they were Factor IX 
transgenic [sheep].
Lovell-Badge. Okay, they were all Factor IX, I thought Holly and Olly were not 
too important. Why did Molly and Polly become more famous that Holly and 
Olly, then?
Ritchie. [laughter] I think people were tired by the time …
Schnieke. It could have been because they were only neomycine positive which 
had happened because you select the cells, and it was a cotransfection, and so 
some of them were with cotransfected Factor IX and with neo [neomycin resist-
ance gene] and there might have been some which had only neo.
Lovell-Badge. I thought that was Holly and Olly that just had the neo and Molly 
and Polly, but …
Schnieke. And that was really to prove that you can use the technology for mak-
ing transgenics. They were all made from foetal fibroblasts.
Colman. Perhaps I can ask about the naming of Dolly, because it really came 
from your staff, didn’t it [laughter]? [To John Bracken:] Was it you?
Sang. We are recording this fact! 
Bracken. Yes, but it was just an off the cuff the remark, to my colleague who 
was there when Dolly was born, and I just mentioned to him that we should call 
her Dolly after Dolly Parton, because of the connection with the mammary cells, 
and I never thought that it would ever be repeated. I certainly didn’t repeat that 
to Ian, so it must have been Douglas [McGavin, at Dryden farm] because imme-
diately you [Ian Wilmut] mentioned it to people in the press, then it became a far 
bigger story.
Wilmut. It was good.
García-Sancho. To follow up with John Bracken, I’m quite interested in the 
process of looking after these animals and approaching them from a veterinary 
science perspective. Because we’ve heard a lot about the science, the laboratory 
science, so how was the experience of looking after the cloned sheep?
Bracken. The only animal that was different to every other animal was Dolly, 
and that’s simply because of the media attention she got, and when the media 
came they wanted to photograph her, and the best way of getting her into a posi-
tion was to give her food, so she associated the media with food, and that is how 
she became more … Well, she didn’t become a pet but she’d certainly become 
far more friendly to people and would approach the gate and stand up into her 
trough. If you went into the place with all the other sheep, she would be the one 
that would be standing up looking, but it was association with food.
Ritchie. John, I think that the first time that she was actually introduced to lots 
of the press, there is a very interesting photograph, where she is actually doing 
that, and I think she was a bit of a diva. But she’d never seen the press, she’d never 
seen lots of people before, and I think it just so happened that she was an animal 
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which was, if you like, very forward and did stand up in her trough and look for 
something to eat.
Griffin. The photo you’re talking about was taken by a now award-winning pho-
tographer, Murdo MacLeod (Fig. 8), and I was told that his wife had to step down 
from her job to meet the demand for that particular photograph [ laughter ].
Schnieke. I think what might also be quite interesting is the critique about the 
Dolly paper, and how many people did not believe that this was a real experiment. 
I think I went to Alan [Archibald] and he explained to me how to do a microsatel-
lite analysis, and so we had done microsatellite analysis for almost all the animals 
to show that they could’ve only come from the [cell] clones. We used maybe five 
markers.
Archibald. It wasn’t very many, certainly
Schnieke. It wasn’t very many, but [enough] just to have some proof, and af-
terwards we actually had to do an almost forensic analysis, to get the proof that 
Dolly came from the mammary cells and [it was] not a cheat, because Nature had 
put the wrong leg on the paper (see Fig. 9) [laughter].
Griffin. That was quite an exercise, and if we go back to the comment earlier 
about the cells coming from the Hannah Institute. Because we were able to get 
those cells directly from the Hannah, transfer them to …
Colman. Alec Jeffreys.27 
Griffin. Yes, and it was also fortunate that that short paper came out in the same 
edition of Nature as the one describing the cloning of 50 mice.28 The two things 
together stopped the criticism dead.
Colman. I think you expanded the number of microsatellite probes you used; 
you did nine or so finally, it was five to begin with, but the DNA fingerprinting was 
done completely independently by Alec Jeffreys at the University of Leicester.
Archibald. I think when you guys cloned the pigs later on we did more then. 
What’s interesting is, if you did it today, you would sequence everything, and I 
suspect there would be a little bit in the corner that would be different, a very 
small bit. So it’s possibly just as well we didn’t have quite the penetrating tools we 
have now, back then. In fact just on, is there any material from any of them left, 
stuck in a freezer somewhere, a cell line, a bit of Dolly?
Griffin. Probably a piece of wool.
Colman. Maybe in Nottingham, because Keith, as you know, made more Dollies 
afterwards.29
Whitelaw. That piece of work is being written up for publication at the minute, 
the work that Keith went on to do, and there was precious little of anything left 
from the original.
Lovell-Badge. From the original cell line?
Whitelaw. From the animals, unfortunately.
Lovell-Badge. So Dolly is also in the museum right?
Sang. The same museum [National Museum of Scotland]. 
Colman. Oh yes, Tracy went down to London [to the Science Museum].
Bracken. When you’re talking about trying to verify that Dolly was exactly 
what she claimed to be, we got an independent person to come and take blood 
from her, the head of anaesthesiology at the Dick Vet [The Royal Dick Veterinary 
School, University of Edinburgh]. He packed it, he sent it away, we, as employees 
of Roslin, never had anything to do with it, and it was obviously independently 
verified, with many strict guidelines to ensure that it was what it was. 
Colman. When you were asked a question, John [Bracken], about the events 
after she was born, the husbandry, I recall that it was amazing that this one preg-
nancy held through to term.
Bracken. Right through the pregnancy.
DNA fingerprinting is a tech-
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Colman. And so, we got worried that maybe she’d die on birth and things like 
that. I recall we had a 24 hour person who was just there with your guys, but after 
the birth I think Dolly wasn’t well – she ran a fever after birth, and so you had 
your vets, and I think we sent our vet in just to add to the number, because we 
were so concerned that she might die in that crucial period just after birth.
Bracken. But certainly my recollection of her immediately after birth was that 
she was one of the most normal lambs that, you know, in my experience, so 
there was no concern on my part that she wasn’t an absolutely normal lamb. I 
think you’re talking of this fever that happened about day three or four, and after 
that, certainly in the first year, eighteen months, there were no other health is-
sues whatsoever. So my recollection is that apart from this fever, which was very 
short-lived and only was a 24 hour thing, the rest of her youth, through to young 
adult was very normal, with no concerns for her health.
Ritchie. I think there was quite a number of us actually at the Dryden [farm] 
that day, because there were caesareans going on, so I actually saw Dolly and saw 
it get up on its feet and actually start suckling very, very quickly, just normal, just 
what I would’ve expected to see in any animal.
Bracken. And no issues as far as birth weight or anything, so she was normal in 
the real sense of the word.
Ritchie. Of course we were pretty certain that it wasn’t a normal Blackface lamb 
[breed of Dolly’s foster mother]. The colour certainly indicated that.
Schnieke. I didn’t think you had that breed on the farm.
Ritchie. We didn’t, it was very obvious that [Dolly] was a Finn Dorset lamb so we 
had no qualms about what was actually running around.
Lovell-Badge. So you’re saying that others at the Institute didn’t know that she 
fIGuRe 8. Murdo McLeod's 
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was cloned. Would they not have been surprised that 
you had a Finn Dorset lamb running in the field?
Ritchie. I don’t think it … Come on, most people 
wouldn’t have recognised it as a Finn Dorset anyway 
[laughter]. To most people, a lamb is a lamb and it 
doesn’t really matter what it is. If you’ve got a decent 
shepherd, decent shepherds will recognise individ-
ual animals but most people say ‘why did you use a 
sheep, we can’t tell which one the cloned one is?’
Schnieke. All three were from different breeds. All 
the mother animals we used were all Blackface and 
then we had the Poll Dorset [Polly and Molly], the 
Finn Dorset [Dolly] and the Welsh Mountain [Megan 
and Morag]. 
Griffin. It was a good choice of breed, very pho-
togenic. If it had been a Texel, I don’t think Dolly 
would’ve been [laughter] … quite as popular. 
Colman. But you mentioned the business of the 
front cover of Nature with the wrong leg [one of the 
back legs of Dolly on the Nature cover was actually 
the back leg of her surrogate mother – see Fig. 9]. 
That was due to erroneous use of Photoshop, and 
of course, I don’t think anyone associated with the 
paper got to see front covers so they couldn’t correct 
that. But it’s interesting to speculate, in view of some of the revelations that 
happened in all the years following Dolly about image manipulation, that there 
was a mistake in the Dolly paper itself. Two panels were identical when they 
shouldn’t have been (in one of the figures of the cells), and it was corrected in 
erratum but nowadays people jump on that immediately and say ‘oh, can’t trust 
these people.’ 
Wilmut. They’ve been redoing the display in the museum, so Dolly’s not been 
on view for a while, and the museum has got a sort of depot down in Granton 
Docks, aircraft hangar size, so I went down there and was shocked to discover she 
actually had arthritis all along her spine. Were you [Bill Ritchie] aware of that?
Ritchie. Only when Andrew Kitchener [curator at the National Museum of 
Scotland] mentioned it. I know Andrew very well.
Wilmut. Because there was a full histopathology done on her after. It’s really 
obvious, but we certainly didn’t detect it when she was alive, I don’t think.
Ritchie. Yeah, but it’s one of these things that seem to be fairly common in ani-
mals which are housed and which aren’t getting a lot of exercise. I think Andrew 
Kitchener has done quite a bit of work on that.
Lovell-Badge. Was it in all four legs or just the hind legs?
Wilmut. I didn’t go into that detail, the spine was what shocked me most.
Ritchie. I think mainly the hind legs, but it clearly was in almost all of the joints.
Whitelaw. Just to echo Bill [Ritchie], Andrew’s got a theory that this [arthritis] 
is because the animal doesn’t live an active life, and he’s basing some of that on 
animals kept in captivity, in zoos, where some zoos have a very active regime for 
the animal, others don’t, and there’s an interesting story there. So I personally 
don’t think that’s a ‘Dollyism’, it’s the fact that she was penned up and limited in 
her activity through her life.
Lovell-Badge. But the infection that killed her was …
Wilmut. Nothing to do with cloning.
Whitelaw. Jaagsiekte.30 
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Bracken. Something about the media. I think it was a very good move on Ros-
lin’s part, that they were so open about Dolly. I don’t know how you restricted 
or allowed certain groups to come and see her, but we had lots of visitors and I 
think that openness and for people to be able to come and see her was a good way 
of ensuring the story of Dolly herself was a positive one rather than that she’s 
under sort of lock and key and nobody’s allowed to see her. I think that openness 
certainly helped the whole thing.
Lovell-Badge. But do you think if she’d been shy and retiring or grumpy and 
aggressive, the story would’ve been different?
Sang. Like the rest of the sheep [laughter]? Although this is the future, which 
we’ll talk about later, I think the standard of openness in discussing what the 
experiments involved and what the outcomes were has really set the standard for 
Roslin that we’ve kept to, and that’s been a very good precedent to have set.
Bracken. Because it would’ve been so easy for the bad publicity, which there 
was some of, to dominate the whole event and that certainly didn’t happen.
Sang. But it gave us a lesson that if you’re open and discuss everything, you get 
a much more positive response.
Griffin. It did for the Institute. It opened up tremendous opportunities. For 
example, both Ian and I were invited to discuss embryonic stem cell research by 
people who were clearly not in favour of any work on human embryos at all. A 
good part of the time after Dolly was born we were the loudest voice – if not the 
only voice sometimes – speaking up for human embryonic stem cell research, 
even though it wasn’t core to the Dolly story. And the changes in law that allowed 
research into human embryos, I think we did contribute quite a bit to that.
Lovell-Badge. I think we’re going to get onto that a bit later.
Ritchie. You’re talking about the openness, and I’m sure Harry had told me a 
story about when Morag and Megan were actually born and the paper was pub-
lished, that someone had come from STV [Scottish Television], and we’d been 
busy at that time and hadn’t been able to accommodate them and tell them what 
was going on. And they said ‘Well, we’ll make up the story’, and they did. I think 
you’d been speaking to the BBC as well, and by the time the story had reached the 
ten o’clock news, the BBC had the story, STV couldn’t then say that this was all 
secret work. But I can remember actually seeing it, and seeing pictures of security 
cameras and saying that this work was secret work at the Roslin Institute. That 
may be what’s helped in the subsequent Dolly furore, perhaps to be a bit more 
open.
Whitelaw. We did miss an opportunity, when we were phoned up and asked 
‘Can we speak to Ian Wilmut?’ we should’ve answered ‘Which one?’ [ laughter ].
Colman. But the press was very scurrilous, sometimes very amusing but some-
times rather mischievous; for example when there was this issue of mitochon-
drial DNA, and the fact was that Dolly was made with a Scottish Blackface egg, 
and so you would expect to find some Blackface mitochondrial DNA in her, and 
indeed it was found. I think it was Steve Connor of The Daily Telegraph [it was The 
Independent] who penned an article with the headline ‘Dolly is a fake or a fraud.’ 31 
Well, that’s not helpful. On the other hand there was the bit when Alec Jeffreys 
published the DNA fingerprinting that tells you there’s a 1 in 1010 chance that this 
DNA doesn’t come from this individual but another one. I did some calculations 
that showed that there couldn’t be more than 106 Finn Dorsets in the world, and 
foolishly told this to a reporter. Next thing I see is the headline ‘Dolly’s mother 
might have been an extra-terrestrial sheep!’ [ laughter ] – now that’s funny!
Lovell-Badge. Alright, shall we do Cupid and Diana?
Schnieke. Yeah, that was sort of the logical follow up, we had made the trans-
genics, and then we had to prove that we could do gene targeting. We had tried, 
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at the same time when we made the transgenics, to target HPRT, but as livestock 
seems to be able to use a different pathway, this wasn’t easy. We did that with 
[David] Melton32 and he was doing it in parallel in mouse (where it works), and 
after we tried it in sheep, there were also publications on some other species, 
which announced it was difficult. And then we had to decide on a different target. 
We were thinking that targeting in somatic cells would not be that easy, so we 
wanted to have some target gene which is highly expressed. We thought about 
actin, and then went for collagen, which of course is very highly expressed in fi-
broblasts. We then did targeting downstream of the collagen, first just the marker 
gene, and then also placing one of our transgenes into the same locus, and then 
the next season generated cloned sheep from these cells.
Colman. The reason we chose a locus downstream of collagen was because 
there were known human diseases where collagen was mutated, and we didn’t 
want the first knockout large animal to be a diseased one, so rather than the 
actual gene itself we wanted to take advantage of the locus [the advantage being 
high expression of the collagen gene].
Schnieke. And I think collagen is now used quite often, to place genes there 
which should be expressed.
Lovell-Badge. And why the names Cupid and Diana?
Colman. Oh, God knows why [laughter].
Schnieke. So first, they were both males, so that was wrong [laughter]. Then 
somebody had the idea that targeting a specific gene had something to do with 
the goddess of hunting, capturing, but that wasn’t from me, I think that was Ron 
[James].
Colman. I don’t know. Could I just end this with just mentioning that names 
can be wonderful. The choice of the name Dolly was a wonderful conception, 
and we continued the names and when we’d made the first five pigs, the cloned 
pigs, we named them. Dotcom was one of them, because anything with dot com 
on the end seemed to be doing extremely well, and the day that paper came out 
the market just fell completely [ laughter ]. There was a Millennium pig, Millie, 
there was Alexis and Carrel, and the origin of the choice of the names was a 1912 
Nobel Prize winner [Alexis Carrel], who got his prize for the very delicate work on 
the human microvasculature, which allowed actual organ transplantation subse-
quently to take place.33 He was a Frenchman who did his pivotal work in America. 
We learnt later on that this guy had been very big in the eugenics movement and 
all the boulevards in France named after him were currently being renamed. I 
got a letter from a famous French embryologist asking us to rename these two 
animals in view of this problem with Alexis Carrel, and he suggested Marie and 
Curie for the names. I just responded, I think I was just shooting from the hip and 
said there’s only so much I can do for the French, and just left it as it was. 
3. funding Dolly
Lovell-Badge. We’d already begun discussing the relationships between Roslin 
and PPL before and during the cloning of Dolly. We also need to discuss the 
wider political and financial context in which the work was done: there were dif-
ferent government departments and funding agencies, MAFF,34  BBSRC,35  PPL 
got involved at some point. The Roslin Institute had a mixed funding stream, 
certainly then and probably still does, and I remember from my time on the gov-
erning council that questions were made about the different funding streams. 
Was that disruptive or helpful on the whole? Was it difficult to get funding for 
the Dolly programme? 
Archibald. I think it was actually a very interesting time, thinking back, what 
was happening twenty years ago. Dolly was born in 1996, and the paper pitched 
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up in ’97, and that was at the end of 18 years of attritional science funding un-
der Thatcher and then Major governments. The Roslin Institute had been suf-
fering cuts along with the other Agricultural and Food Research Council insti-
tutes over that long period. So 1997, I’d argue, was a sort of inflection point, the 
Blair government who put significant new money into research, and we’ve now 
reached the point where we’ve endured five years of flat cash, in terms of the sci-
ence budget, 2010 to 2015. As from 1 April this year, BBSRC was the only research 
council to take a funding cut, and that’s not in real terms, that’s cash cut, so it’s 
even greater. We’re possibly heading back towards territory where government 
doesn’t appreciate the value of research, it’s almost like we’ve come full circle. Ian 
will remember well the issues after the Dolly project, when the paper came out 
and the subsequent funding challenge.
Wilmut. The funding for this project was cobbled together and I think I men-
tioned earlier on that it was a DTI [Department of Trade and Industry] pre-
competitive package that collapsed because one of the parts of the package was 
Martin Evans.36 His lab was supposed to be trying to produce stem cells from 
cattle embryos, and we were supposed to be taking those cells and trying to make 
chimaeras with them by injecting into blastocysts. When we got foetuses, when 
the result came back, we obviously sent some of the cells there: the cell line which 
we’d been putting into cow embryos was actually probably rat … So it wasn’t bo-
vine and that package stopped.
Lovell-Badge. So those cells had come from them because they were trying to 
do rat stuff at the same time.
Wilmut. Well, they would possibly have been used as feeders. They certainly 
weren’t bovine, maybe I’m getting confused about what they were.
McWhir. In my memory they were mouse.  I had exactly the same problem 
when I was working in Martin’s lab, I was trying to isolate porcine and cattle ES 
[embryonic stem] cells, and I thought I had a pig line, but fortunately we karyo-
typed it before we told anybody. It turned out that it was mouse, so it’s very easy, 
when you’ve got both cells and you’re working in the same tissue culture, to get 
cross-contamination.
Wilmut. So we then got money from a European grant, 1994 to ’96 or that time 
period. I’m sure the Institute put its hand in its pocket and gave us some money 
at some point, yes?
Griffin. Yes. As I said earlier, I think it was for the sheep, in relation to the sheep 
season.
Wilmut. We did get some MAFF money, but as Alan [Archibald] mentioned, on 
the day when we announced the birth of Dolly, MAFF said they were going to 
stop the funding, which seemed something of a PR own goal.
Griffin. There’s a broader funding issue, or a tension that the Institute’s always 
been under, ever since I joined the Poultry Research Centre in 1978. This comes 
out very strongly with every visiting group. We’re supposed to be doing basic sci-
ence, say the academic members, or we’re supposed to be doing something useful 
for the industry, and all the work we’ve been discussing actually falls between 
the two stalls. It’s a bit ironic that Dolly’s creation is the single most important 
piece of basic science this Institute’s ever delivered, in terms of its impact on the 
understanding of cellular differentiation. Alan [Archibald] has talked about the 
funding for the science project, but all throughout the period from 1980 onwards, 
funding from the Ministry of Agriculture, DEFRA, whatever form it took, has 
always been decreasing, and they’ve been moving away from providing funds for 
more basic science. Whether this project as a whole would have ever qualified for 
Department of Education and Science funding … I’m not sure it would’ve done.
Archibald. I’m sure the reviewers of such a grant proposal to BBSRC would’ve 
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said ‘do it in mice first.’ But I think one of the really important things, as far as 
Roslin was concerned, was that ultimately, when we sold the technology on to 
Geron, that funding package [that Roslin got from Geron in exchange of the tech-
nology] saved the Institute because that was the point when the DEFRA money 
completely fell off the cliff and essentially went to zero. That Geron money al-
lowed us to survive that period until we picked up our position, getting good 
grants out of BBSRC. Without that I think the Institute wouldn’t be here.
Lovell-Badge. How was the relationship with PPL at this time?
Colman. After Dolly we hired Keith [Campbell], he went to the dark side. Keith 
was unique in many ways and he of course made the pig project go successfully, 
but he always had itchy feet, and I think academia was more aligned with his per-
sonality in many ways. In 2000 he went to Nottingham from us, so he was with 
us for about two years and spent quite a lot of time in the US where the pig work 
was done. Dolly was the only time the share price [of PPL] ever got above the flo-
tation, and it was about four days, I think it got over £5, but it was so close to the 
flotation that none of the directors, like myself, who had shares could ever make 
any money – some of the staff did, because they could sell their shares, which had 
been issued at low prices. But Dolly was the height, the zenith, I’d say, of the share 
price and it was downhill from there on, and we raised more money after that 
time, and we turned towards embryonic stem cell work on the side,  while trying 
to move the products to the clinic. The manufacture of the biopharmaceuticals 
was very successful in a sense that we could make a competent preparation of al-
pha-1-antitrypsin at $16 a gram. For something that could go down into a person 
this was enormously cheap, so the concept was right, but the fact is that alpha-
1-antitrypsin failed probably because the post-translational modifications were 
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not the same, the different sugars. What happened 
was the lifetime in the human blood, the turnover 
was much greater with sheep-made human products 
than the human-made products, so we went to a dif-
ferent indication which was  CF [cystic fibrosis], but 
it didn’t work there, didn’t do what it needed to do. It 
was always an untested hypothesis and it didn’t work 
so, eventually, I left in 2001. When did you leave An-
gelika [Schnieke]?
Schnieke. Very early in 2003.
Colman. In 2003 [PPL] was acquired by hedge funds 
and that was the death knell. I mean, they acquired it 
because they wanted to …
Schnieke. Get the patents.
Colman. Yeah, get the patents and split the company, so the American side sur-
vived that, and got taken over by others.
Lovell-Badge. The patents were bought in 2004 by Pharming, the Netherlands 
company. But then something ended up in the University of Pittsburgh?
Griffin. Has anybody taken the technology and produced a product that’s gone 
on to clinical trials?
Colman. No, not from PPL.
Griffin. Not anybody in the world?
Colman. There are pharming products in very small niche markets, but they 
have been approved and they are used, yeah.
Lovell-Badge. And is that because they are difficult, because people don’t like 
them? What’s the reason?
Colman. The time to market is much extended when you turn to large animals 
– I mean, cloning doesn’t affect the gestation time of a sheep or a cow, it’s still 
a long time. Cell culture methods improved markedly in the yield themselves, 
[became] much more controllable. A lot more competence in engineering has 
been devoted to getting cell culture products to the market, and so, really, the 
pharming concept was best with proteins that you needed in very large amounts, 
cheaply. Alpha-1-antitrypsin is a very good example. I don’t think the coating fac-
tors were a good example because you didn’t need huge amounts of those, and I 
don’t think Factor IX ever worked, it’s down to carboxylation. 
Schnieke. No, they all worked but you never got very high expression levels 
because you needed carboxylation. We did some protein C work, some Factor VII 
work. 
Colman. So, they all worked well?
Schnieke. They all worked, yeah.
Colman. The niche we were aiming at was, originally, this large volume, low 
cost, and just took too long. And the one [protein] we developed didn’t work, 
unfortunately, but we didn’t know that to begin with.
Archibald. Well, there was also the suspicion that when PPL had the relation-
ship with Bayer, Bayer already had alpha-1-antitrypsin as a product they were 
trying to develop with different technology and that didn’t seem like a great idea.
Schnieke. Yeah, that’s true.
Archibald. And then, as you say, the hedge fund:  basically the money [PPL] had 
in the bank was greater than the value of the company, if I remember correctly.
Colman. Yes, yes. But it did well for a time, and when it floated in 1996, people 
said you could float £10 notes at that time,  so capitalism helped us to begin with 
and took us down in the end, and you just had to accept that. 
Archibald. Am I correct in thinking that when the company was founded, the 
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Scottish Development Agency [SDA],37 as it was then, were a key broker in get-
ting the company started? And that there wasn’t really that kind of government 
level intervention in other parts of the country, so it was a kind of advantage of 
being here?
Colman. I think it was. I was already here with Helen [Sang] and learnt about 
John Clark’s work, and the SDA sure did help, but it wasn’t as if there was any 
thought of having that work done anywhere else in the country, because the 
inventors were at Roslin. When we started Caledonian Transgenics, we started 
down in Birmingham, where I was at the time and some of the people were. Then, 
with the large animal work, Andy Carver had to drive up in these cars to perform 
his microinjection which he learnt from you guys. The molecular biology was be-
ing done in Birmingham and ultimately it just didn’t seem sensible to have work 
going on two sites. Then we moved the company up to King’s Buildings [in Ed-
inburgh]. That was where we first started. Subsequently we acquired a purpose-
built building on the Roslin site, surrounded by non-transgenic sheep, which we 
joked acted as decoys for any persons who would wish us ill. People thought, ‘Ah, 
do you keep your transgenics near?’ and we said, all the sheep in the fields round 
Roslin are decoys. Really, it was very enjoyable, working with the Roslin Institute, 
all of us on the same site.
Wilmut. Paul Simons was the person who started the gene injection work in 
mammals at Roslin.
Colman. Where, in your place?
Wilmut. Yeah, I mean, when we started, the work you mentioned from Brin-
ster and colleagues at the USDA [labs in Beltsville, Maryland], was published, on 
actually how to do it, and we didn't know.38 It was Paul [Simons], with a little bit 
of help from me, who found the pronuclei, and his PhD had been injecting into 
cells, so oocytes were a handy size thing to work with in comparison to cells. But 
of course they are lipid filled, so you can’t easily see the pronuclei, and that was 
the knack, and he did all the early gene injections for us.
Lovell-Badge. Yes, I remember visiting once and he showed me how to centri-
fuge the eggs to separate out the pigment and lipid. So clearly there was this in-
teraction between the different sides of science, the molecular biology, the clon-
ing work, the reproductive biology, cell cycle stuff. I assume everyone thinks that 
was very important for the success, both of Roslin and, at that time, PPL, because 
you had good interactions.
Colman. Yes, there were tensions at times, inevitably, but it was very productive 
for us, and hopefully for them, too. But the breakthrough technology came from 
Roslin and we learnt it by copying them, and exploited it. It was a very nice time, 
I think, because everybody was relatively young then [ laughter ].
Lovell-Badge. And did that relationship maintain itself throughout?
Colman. Yeah, at the end, obviously, there was less interaction because … 
Schnieke.  Geron,39 I think once Geron came.
Colman. Yeah, once Geron came we started doing the nuclear transfer out of 
our facility. It was a lot more expensive for us, because all our sheep were flown 
in from New Zealand on a jumbo jet.
Lovell-Badge. Was this to be scrapie-free?
Colman. Yeah.
Archibald. And one of the ironies of that, of you shipping in scrapie-free ani-
mals from New Zealand, was that your farm at Ormiston was within sight of 
the Institute’s former farm at Skedsbush, which is where the Institute of Animal 
Health’s scrapie-infected flock was going [ laughter ].
Colman. That was just one of the hazards. We were trying to make this clini-
cally qualified protein and we were worried about coal dust getting into all the 
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equipment filters and everything. There were all 
sorts of challenges.
Wilmut. Robin, if you were to make a compari-
son and ask about relationships with PPL and with 
Geron … I’m biased, but I think the relationship with 
PPL Therapeutics was much more collaborative than 
with Geron [ general affirmative noises ].
Lovell-Badge. So they [Geron] were brought in be-
cause you needed money for …
Wilmut. No, they licensed our technology and the 
Institute got a large amount of money, I don’t remember the numbers but it was 
a lot of money. The sale was assessed by some parliamentary committee, wasn’t 
it? 40 And the Institute got a pat on the back for what it had done, that may be 
right, but part of the deal was that Geron would fund work, and the way in which 
it would be managed would be that they would agree a year or two’s work, and 
they’d come and assess it every now and again. At the end of the first year they 
would make a long-term assessment and either indicate at that point that they 
were going to stop it in a year’s time, or re-extend it back to two years, so that you 
never had less than a year’s notice as to when things were going to be stopped. 
And they came one April and said it [the nuclear transfer work] was okay, came 
back in June and said they were going to stop it, and it was stopped in August. 
Colman. Could it be that it wasn’t worth pursuing at the Institute?
Wilmut. We felt that they’d bitten off more than they could chew, because they 
had the telomerase work, human embryo stem cells, which became their biggest 
thing for a while, and nuclear transfer. What they did was they shifted the money 
from nuclear transfer to stem cells and so for a while Roslin had the biggest group 
of people working with human ES cells in the United Kingdom. It probably did 
the Institute quite a lot of good. Quite a number of individuals benefited from 
that opportunity. It was the people who were involved in the cloning, which had 
produced this wonderful opportunity, who were chopped off.
Lovell-Badge. What year was it that Geron came in?
Schnieke. It was after Dolly and so the reproductive cloning was just starting 
[in animals]. 
Wilmut. It would be a few years after Dolly, though, because what they actually 
did was to buy the company we’d started. The Institute started [another] com-
pany, Roslin Biomed, to develop the cloning technology and to licence the tech-
nology to various people including PPL, and they [Geron] bought it.
Sang. And Roslin Biomed had 3i investment,41 and once you have that invest-
ment, the investors are in control, and they wanted to make the sale to Geron, 
isn’t that correct?
Wilmut. Yeah.
Griffin. The CEO of Roslin Biomed was Simon Best, and Simon had been previ-
ously working on bringing transgenic tomatoes into the UK. So he had a rather 
complicated history of pop music business and transgenic tomatoes [ laughter ].42  
Sang. Didn’t they start up a company out of their stem cell business?
Colman. Yes, it’s called Asterias and they’re running a clinical trial now, on age-
related macular degeneration, in the US.
García-Sancho. I wanted to, ask about the Scottish Development Agency and 
the role of these kind of agencies in promoting what was Caledonian Transgen-
ics. Was that a response to the scientific policies of the time on prioritising ap-
plied research and commercialisation of basic research?
Archibald. When Rick Lathe, who was the original driver of making proteins in 
milk, was running the molecular biology group, because Rick had come from a 
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biotech background  we were very active trying to sell the idea to biotech com-
panies and big pharmaceutical companies before we’d done any work at all. That 
included speaking to BTG who were supposed to act as a kind of UK-wide agency 
for developing new biotech.43 My recollection is that the Scottish Development 
Agency – this is 25 years ago – had had successes in terms of creating Silicon 
Glen,44 and they were looking for something in the biotech space, they wanted 
something to do with biotech as well, which is why we managed to attract their 
attention. They played some role in raising funds getting someone to say they 
were going to put some money in – makes it easier for the second person or the 
third person to put money in. I think it kind of felt like that, that they’d come 
with the catalyst to getting the funders on board, to create what, as Alan [Coman] 
said, was Caledonian Transgenics at the time.
Colman. It went down really well in the US [ laughter ]. Caledonian, they had no 
idea what that meant.
Archibald. We made up some tartan logo for it as well if I remember correctly.
Colman. I’m not sure about that.
Archibald. There was some notion, well, maybe it was a spoof tartan thing we 
did, I can’t remember.
4. Species choice
García-Sancho. Alan Colman has mentioned that, after Dolly, PPL hired Keith 
Campbell to run a programme on pigs. I just wanted to ask whether in the early 
years of the pharming programme or even before, there had been work aiming to 
produce genetically-modified pigs. You had talked about sheep, about eggs and 
chickens, about goats, but what about pigs?
McWhir. Ian will correct me if I’m wrong, or Alan [Colman], but I think the fol-
low on work in terms of species progression from the supermouse45 in 1982 was 
pigs, with the same [genetic] construct, was it not?
Lovell-Badge. But that wasn’t pharming.
McWhir. Sorry, did you specifically mean pharming?
García-Sancho. I did say pharming, but I meant more generally the roots of 
work on genetic modification of pigs.
Archibald. Well there was Bill Wilander who worked with the American Red 
Cross, and his pig project was to make, I think it was human albumin in pig blood. 
It was to produce product for enhanced plasma.
Whitelaw. It was protein C.
Schnieke. But it’s not so easy to milk a pig, so for pharming the pig is not the 
best model.
Archibald. Although someone did do it, someone did.
Colman. It’s not easy, they’re dangerous. [ laughter ]
Sang. There was somebody who wanted to make proteins in the semen of pigs, 
because you can get semen from transgenic pigs.
Colman. A little known fact.
Bracken. Speaking about the pig, versus the sheep, it is a completely different 
ballgame, actually, producing work for nuclear transfer when using pigs. The 
animal is bigger, it’s more costly to keep, the superovulation is better but is more 
difficult to achieve, the anaesthesia is more difficult, the surgery is more difficult, 
and the fact that the pig itself, even if you get it pregnant, has a mechanism to 
stop a pregnancy if there’s less or more than four or five viable embryos. All these 
things are against using the pig, compared to the sheep, unless you really want 
that as a species, and then you have to tackle all these individual problems.
García-Sancho. Were there conversations between the veterinarian people and 
the scientists, in order to choose one model organism? Would you share that in-
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formation with the scientists doing the transgenic work?
Bracken. I think the pig was initially used because of the xenotransplantation, 
that was why they moved from sheep to pigs. But as far as obtaining the oocytes, 
we actually would superovulate the pig, bring it over to the surgery unit, do an 
initial scan of the ovary to check whether it had superovulated or not. If it hadn’t 
superovulated, we would discard it from the group, but then after that, two of us 
would come in at midnight and scan these ovaries with the developing follicles, 
and we would scan them every two hours, initially, to find out when ovulation 
occurred because an ovary with follicles on it is very easy to see on an ultrasound 
scan, but when the ovulation occurs, because the oocyte has then dispelled the 
fluid, it’s very difficult. So you could actually determine when ovulation occurred, 
so we would scan at midnight, two, four, and six, and we could then pick up a 
surgery list of when the animal ovulated, so the ones that ovulated first were the 
ones that we did surgery on first, and then at six o’clock, when surgery started if 
they hadn’t ovulated these were then used as recipient pigs. But that took a lot of 
learning and effort to do, because we would be doing three sets of pigs in a week, 
so two of us would be coming in three consecutive nights to work through the 
night, then do the surgery and that in itself was a big, big effort to achieve what 
was far easier with a sheep.
Whitelaw. What was PPL’s drive into pigs?
Colman. Xenotransplantation, the major thing was to knock out a gene called 
alpha-1,3-galactosyltransferase.46 
Whitelaw. So would it be fair to say at that time that there were several players 
in the bioreactors [i.e. pharming]? There was yourselves, there was Pharming, 
there was [the company] GTC, and American Red Cross, and you each picked dif-
ferent species. Was there a driver for that or was it a business decision?
Colman. Well, we picked sheep because you [Roslin Institute] picked sheep 
[laughter].
Whitelaw. Well, we had that expertise. Because American Red Cross did pigs, 
GTC did goats, and Pharming did the cattle, didn’t they?
Colman. Yes.
Whitelaw. So was that wrapped up in the patent positions or was it just where 
you were?
Schnieke. No, I think the patents were more on the promoters than the species.
Colman. We were always battling with Pharming over intellectual property is-
sues and we usually won, but they bought all our patents at the end when PPL 
went belly up, it’s sort of a pyrrhic victory, of course. Their first published animal 
was Herman the bull, which was, unfortunately a male so it couldn’t make milk 
in the conventional way. Well, we found ways of getting milk out of males, I have 
to say, which we didn’t pioneer, but we could evaluate a line through the milk 
from the bull. 
Whitelaw. So the drive into pigs was purely xeno[transplantation] then, around 
the world?
Colman. Absolutely, absolutely xeno. 
Schnieke. You use the best model for the project you want to work on.
Colman. We had considered, because it had been mentioned in the literature, 
ostriches [ laughter ]. It was serious because physiologically, particularly the cardi-
ovascular circuits were more human-like, because the ostrich walks on two legs.
Whitelaw. Can you catch them?
Colman. People farm them.
Wilmut. There weren’t any volunteers.
Lovell-Badge. So, how many cells in a newly-laid ostrich? [ laughter ]
Sang. Actually probably about the same. I was talking to Megan Davey 47 yester-
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day about comparing quail and chicken and actually at the very earliest stages of 
embryogenesis, in quail, chicken and emu, the embryos are the same size.
Colman. We never got that far in that evaluation of ostrich eggs.
Whitelaw. You couldn’t catch them?
Colman. No, we never got serious about them.
Archibald. So in terms of pigs for nuclear transfer, the Roslin-PPL team were 
second, we were scooped? 
Colman. Well, actually, that was quite interesting, yes and no. This work was 
led by Keith [Campbell]. The first five pigs, no doubt about it, were cloned by us, 
and they wrote up a paper by Dave Ayares and colleagues, who worked at the PPL 
facility in Roanoke, Virginia, USA. They wanted to submit the manuscript to Sci-
ence. As CSO of the company, I vetoed that (big mistake) and said, why don’t you 
submit to Nature, because Nature’s British and we had a tradition with Nature 
at the time.  Also, Nature got in contact with me because they’d heard rumours 
about this work and they said, well, if you submit to Nature, we’ll give you a 48 
hour review, we’ll give you a front cover if it’s accepted and a News and Views 
opinion piece. So I said yes, and so we redrafted it, submitted it to Nature but they 
didn’t do it in 48 hours, they did it in a much longer time, and then they sat on it, 
they accepted it but sat on it, and the reason they sat on it turned out to be they 
wanted to publish a paper by Robin Weiss on viruses in pigs, so they wanted to 
have an article disclosing the first cloning of the pigs to facilitate making the per-
fect pig for xenotransplants next to an article highlighting the dangers of putting 
pig organs into people. Meantime, a Japanese group, who started cloning their 
pigs after our pigs had been born, submitted a one-pig paper, if you like, to Sci-
ence. Science accepted it in record time and got in touch with me, and asked if I 
could write an opinion piece on it quickly for them. They perhaps shouldn’t have 
chosen me, because I immediately contacted Nature and said “Look, you buggers, 
this is what you’ve done to us by hanging on to our paper.” So what Nature did 
immediately was to publish it online, so the electronic version came out on the 
same day or a day before, maybe, the paper version of the Japanese group, who 
had not made an online publication. So, yes and no, that’s why I say yes, we were 
definitely first but we were delayed by Nature. They just held onto it so they could 
put the two papers together, and we weren’t informed about that at all.48 
Schnieke. Was that the knockout paper?
Colman. No that wasn’t the knockout, that was the cloning paper. We weren’t 
first on the pig knockout paper, we were first on the double knockout, second on 
publishing the [first knockout paper], to an American group. But PPL were the 
first group in the world to make a large animal knockout [a sheep].49 
Lovell-Badge. So no one ever made embryonic stem cells from the pig, or sheep?
Colman. I don’t believe so, I think iPS cells have superseded them, and they 
make those from those species.
Whitelaw. But there’s only one group that’s shown that such iPS cells will go 
into the germline. Steve Stice has showed that, there’s a little bit of controversy 
over that, in that the paper for germline transmission [i. e. the foreign gene pass-
ing on to the offspring] was validated by PCR rather than a Southern blot, which I 
think the academic community would have bought, and certainly those cells are 
now no longer able to do so.
Colman. So how did they do it, was it chimaera work with the cells, or what?
Whitelaw. Yeah, it was chimaera work and then germline transmission, if I re-
member correctly. So it’s still a challenging, very much a challenge to get any 
robust cells. In fact, Jim [McWhir’s] cells, the TNT cells, are as good as anything 
else that’s ever come out, really, from the academic community.
McWhir. Oh no, I don’t think so. We didn’t have extensive differentiation detail. 
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Whitelaw. That’s correct, from the point of view of differentiating those cells 
into lineages there’s quite a lot of progress in the iPS but actually going in and 
making an animal, that’s still not possible.
Lovell-Badge. Pharming in birds, is that happening now?
Sang. Yeah, we still have it ongoing, actually. The first therapeutic product 
made by extracting from the eggs of genetically modified hens was licensed in 
Europe and the US last year. It’s for a lysosomal storage disease so it’s sort of an 
orphan drug route, that’s how it’s gone through the regulators and it’s being sold. 
The company that started out as AviGenics became Synageva, and was bought by 
Alexion which is quite a bigger company, last year, for a lot of money. So there’s 
now a product from hens. 
Colman. What is it, what part of the hen?
Sang. From the egg, the egg white.
Colman. The egg! So it actually works …
Sang. It works, we did it several years ago and we can now make proteins in 
eggs. We can make a gram, about a gram per litre.
Lovell-Badge. So that came out of the work that was done.
Sang. I think we worked in parallel. It’s one of those things, it was discussed 
about 30 years ago, there are very few proteins in eggs and it’s relatively easy to 
purify proteins from egg white, because it’s relatively simple to mix the proteins. 
So if you know anybody who wants to invest we have a product that we’re de-
veloping [ laughs]. It’s very interesting to hear about alpha-1-antitrypsin, actually, 
glycosylation might be better in the hen’s egg than milk.
5. Dolly’s legacy
Lovell-Badge. We’ve covered several areas now. Going back to Dolly and clon-
ing, things we had around the same time were the first embryonic stem cells, 
and so this led to the idea of therapeutic cloning to drive patient-specific cells. 
There were also fears of reproductive cloning, and Ian [Wilmut], you were prob-
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ably asked to provide evidence to various committees about this, and you know 
that initially in the UK, the Human Fertilisation and Embryology Act didn’t really 
permit derivation of human embryonic stem cells, so there was a big campaign to 
get that Act changed, which happened in 2001, and that also permitted therapeu-
tic cloning, somatic cell nuclear transfer.50 This was all triggered by Dolly, so Ian, 
you were very much involved, I suspect.
Wilmut. In primates, including humans, the Roslin procedure doesn’t work, 
the primate oocytes are different. Last year a couple of labs showed that primate 
oocytes are much more sensitive to inadvertent activation, so you get a partial 
activation, which then messes up the oocyte and reduces its ability to respond 
properly when you really want it to activate. 
García-Sancho. People normally know what happened with Dolly and the nu-
clear transfer technology, but I guess less people would be aware of what hap-
pened afterwards and where the technology went and where it was applied and 
what it has enabled, and what lines of research it opened.
Griffin. There are two elements to that. One is, who is cloning now and for 
what purpose, and is it bringing in any significant revenue? And the second is 
more fundamental:  what the consequences are of understanding that cells are 
much more plastic than we ever thought they were? The first one should be easy 
round the table: Who knows who is cloning what, at the moment?
Whitelaw. I’d say there’s a third legacy in that it had such an impact on society 
that it accelerated the public’s desire to see this type of science, biology and ge-
netics in general, in the media. Prior to Dolly, it was very hard for you to get a 
story into any newspaper, and since Dolly, newspapers and media are presenting 
our science all the time. I think there was a step change at that point, and it was 
down to Dolly. I don’t know if people agree with that.
Archibald. I think that’s hugely overstated Bruce, science had mattered before 
Dolly.
Ritchie. But I don’t think it happened so much in public, in newspapers.
Archibald. Yes, it did.
Sang. There’s also an element of coincidence as well as consequence, and no-
body could pick that apart. But I do think it had a huge boost in a sudden freeing 
up of scientific, bioscience thought. You’ve broken down barriers here and we can 
think about doing things in a different way, and we have things like that happen 
every now and then. At the moment the artificial nuclease, the CRISPR-Cas9, is 
having that same sort of freeing up effect, of letting people think about all sort 
of different ways they can use the technology to make faster gains of knowledge.
Colman. I think I take a slightly different view. For me, the principal legacy was 
the confidence it gave the scientific community that it was possible to reprogram 
an adult nucleus down to a pluripotent state, much more embryonic. I feel that 
the motivation that the creator of iPS cells, [Shinja] Yamanaka, had was in part 
inspired by Dolly, inspired by the frog work, inspired by embryonic stem cells 
being made from humans and things like that. All these things were important. 
You know, for 30–40 years before 2006, when Yamanaka’s first reports came out, 
I had been under the impression you just couldn’t separate the nucleus from the 
cell, get it reprogrammed from the adult to embryonic state. I thought, adult to 
the larval state, yes, but there was something special about the adult state, it just 
won’t work, and that was broken by one experiment. It was very surprising, and 
that, to me, was the scientific legacy of that demonstration.
Whitelaw. So, although that’s probably the biggest thing, there are companies 
which are still using cloning, but finding out the details of exactly what they’re 
doing is extremely hard. There are research groups who are using cloning tech-
nology – Angelika [Schnieke] across the room is a wonderful example of that – 
CRISPR-Cas9 is a bacterial 
gene editing complex that 
has been coopted for genetic 
engineering since 2012. It 
enables hilghly precise ge-
netic changes.   
35
and there are still pockets of people trying to research nuclear transfer per se, al-
though that’s a very small part. So the actual technology is there and is used, Alan 
[Colman]’s correct. Everyone, I think, agrees that the big transformation is that it 
has made us believe that we can do things to cells that we couldn’t do before, and 
that’s opened up … Well, it’s fuelled the human stem cell effort.
Lovell-Badge. Regenerative medicine in general?
Whitelaw. In general, absolutely. 
Lovell-Badge. I’m thinking about the timeline, human ES cells were in 1996?
Colman. Primate ES cells were 1995, human ES cells were 1998.
Lovell-Badge. And then the two items together [Dolly and ES cells] with the 
idea of somatic cell nuclear transfer, maybe therapeutic cloning. There was al-
most an immediate response to try a worldwide ban on reproductive cloning, 
even though I still can’t think of any reason for doing it.
Colman. Vanity.
Lovell-Badge. Vanity is the only one [ laughter ]. Then, I guess iPS cells weren’t 
until 2000s.
Colman. 2006 was the mouse, 2007 was the human, but the lead up to that was 
quite interesting. Yamanaka spoke at conferences I went to, and we all knew what 
he was doing, and just no one thought it would work, the way he was doing it. 
But the fact he was doing it was because he felt something would work. I was just 
amazed it worked, it seemed such a crude way of conquering a problem that had 
been so refractory for so many years, but it worked.
Lovell-Badge. A lot of work has gone on looking at reprogramming to make 
iPS cells and the mechanisms involved. I guess people haven’t done so much on 
somatic cell nuclear transfer, and looking at the mechanisms. Although, I guess, 
John Gurdon’s still …
Colman. No, I don’t think John is really …
Lovell-Badge. He’s interested in how you reprogram a somatic nucleus back to 
an embryonic state, he’s still using frog eggs.
Colman. He’s still using frog eggs but I think he’s addressing different questions, 
not trying to work out how the reprogramming takes place. 
García-Sancho. Now that we are discussing the legacy of Dolly, it looks like 
the main knowledge that was gained [from her] was about the plasticity of cells, 
about the possibility of programming and reprogramming cells. Could one of 
the messages of the story be that even though in the 1980s and 90s there was a 
push for applied science and the creation of spin-off companies, scientists con-
tinued doing basic science:  their main motivation was looking at the fundamen-
tal mechanisms of the cell rather than producing animals that may have a com-
mercial output? 
Sang. I think you’re right, in the past and probably in the future the Roslin 
Institute will be pressured to become more applied, but I don’t think you have 
a viable research institute if you don’t have your feet in fundamental research, 
so we’ve always managed by nifty footwork to keep some basic research going as 
well as the applied research.
Schnieke. I think I would also say that after Dolly almost all knockout, trans-
genic, any type of genetically-modified animal in livestock was done with the 
nuclear transfer. People have given up on microinjection because it was so inef-
ficient. They [still] do the viruses in the chicken, that’s a separate one, but almost 
everything else is made with nuclear transfer. There are still people working on 
xenotransplantation, there are more and more people working on porcine mod-
els for human diseases, and that’s in the area of diabetes, of cancer, of cardiovas-
cular disease, of muscular dystrophy, cystic fibrosis, and it’s all done with nuclear 
transfer. Right now, the CRISPR technology is coming in and it’s a bit of a mix, 
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depending on what you want to do, you either do it in combination with nuclear 
transfer or you do it directly in the embryo.
Colman. Do you think it’ll be completely superseded? That most of the uses 
that currently are nuclear transfer will be taken over by CRISPR?
Schnieke. Depends on your question. For example, for xenotransplantation you 
need to get a large number of transgenes into it, CRISPR doesn’t really help you 
there. If you just want to knock out a gene or make a small modification, it is fine.
Whitelaw. I’d say that, from an agricultural endpoint, the CRISPR and direct 
injection have certain advantages. This doesn’t exclude cloning, in the biomedical 
world there are many reasons why nuclear transfer will still be a dominant force.
Ritchie. One of the other fields where nuclear transfer will still be used in is 
endangered species. I saw a publication not long ago on several different endan-
gered species, in which they were using cells from nuclear transfer and putting 
them into a rabbit. So, there’s still some experimentation going on there.
Lovell-Badge. And also for valuable animals, whether it’s cows or dogs.
Whitelaw. Yeah, possibly.
Lovell-Badge. I mean, South Korea …
Whitelaw. Yeah, in the pet world there are different drivers, aren’t there? Alan 
[Colman]’s mentioned already that some companies are just run by rich individu-
als. And that certainly dominates the pet world. 
Lovell-Badge. Not just pets but also police dogs and things like that, sniffer 
dogs. I thought that’s what they were cloning.
Archibald. Come on!
Colman. Sniffer dogs? 
Archibald. These are the ones that are finding the cheese sandwiches instead of 
the turkey sandwich [ laughter ].
Ritchie. That’s very good PR, if you could clone something like that.
Wilmut. So what would the Home Office view be on nuclear transfer?
Lovell-Badge. You’d have to have a good reason for doing it, it depends what.
Wilmut. When I was last thinking about this and talking to inspectors, that was 
the answer – you couldn’t just do it to multiply [organisms], and I don’t think it’s 
regarded as part of normal agricultural practice, is it? So you can’t just do it in 
conventional animal breeding, can you?
Lovell-Badge. In the UK you can’t. 
Sang. And in the US?
Lovell-Badge. In the US you can.
Archibald. I think the way the law stands at present in Europe or the UK is you 
cannot put offspring of clones into the food chain never mind clones themselves.
Lovell-Badge. That’s a European law, not a UK law.
Griffin. That would be clones by nuclear transfer, not by embryo splitting.
Archibald. They don’t know what they’re doing, basically.
Griffin. Ian [Wilmut], what’s the current status of the health of clones?
Wilmut. I don’t know. You probably know more than I do, Angelika [Schnieke].
Schnieke. It’s still an unpredictable thing. Sometimes modified cells get almost 
the normal litter from the pigs, and all the animals are healthy, and with other 
animals, with other cell clones, we have problems. Then we get smaller litters or 
they have epigenetic modifications, and it’s very difficult before we do the nuclear 
transfer to know what happens. It is getting better. It has become more efficient, 
we have 50% pregnancy rates, but we really can’t completely predict if we’ll get a 
healthy animal or not.
Griffin. And does that vary with the cell line?
Schnieke. It could also be with the clone. We don’t have cell lines, it’s all pri-
mary cells, and even if you have one clone or another from the same primary 
37
cells, you could have a difference, but it can be different reprogramming, it can be 
anything. But it’s efficient enough.
Lovell-Badge. How many attempts doing nuclear transfer and how many 
healthy animals born?
Whitelaw. How many reconstituted embryos for one live birth?
Schnieke. How many reconstituted embryos? We actually only have one nu-
clear transfer session a month and that’s not every month, so it’s not that often, 
and we get a reasonable number of lines.
Whitelaw. To summarise, the inefficiencies that were seen in the early days are 
still there. The vast majority of work has been done on the pig, and there have 
been improvements. Some of the commercial setups claim to have made signifi-
cant improvements but some of the original issues are still there, at a variable 
rate.
Schnieke. Once you have the cell isolate which you know works well, then usu-
ally you get your animals, but it’s never 100% guaranteed.
Whitelaw. And again it depends what you’re trying to do. Take Angelika’s work 
where she’s trying to generate human disease models. You don’t need a hundred 
founder animals, you need one.
Schnieke. Just one.
McWhir. I was interested in your comment that once you get a line which works 
well, it continues to work well. It does suggest that there is something about the 
donor cell.
Schnieke. Yeah. But you can follow your same protocol of work with kidney 
cells, and if you isolate a good batch, usually you get your offspring from it. Then 
you do the same thing again from another animal and you might not have it.
McWhir. Do you think this could be accountable by imagining that there are, 
perhaps, sub-karyotypic abnormalities in long-term tissue culture cells that aren’t 
present in embryo-derived cells or primary cells? 51  
Schnieke. They’re all primary cells.
McWhir. Then what do you mean when you say, ‘when you find a cell line that 
works?’
Schnieke. We do a cell isolate and then we freeze them down, and when we 
have the cell isolate, it usually will give you offspring but the rate can still vary 
after your manipulation.
McWhir. So you haven’t got a conventional cell line, but you do have a popula-
tion of cells that have been multiplied in vitro?
Schnieke. Yes, because cell lines to me means that you have a cell which just 
grows and grows and grows, and of course those you can’t use to make nuclear 
transfer animals.
Archibald. But your question still applies, Jim [McWhir], because those sub-
karyotypic lesions could occur in the first couple of [developmental] passages, or 
they could be epigenetic.
Schnieke. Yes, but it is one of those questions where people have tried to get a 
handle on it, they have looked at the epigenetics, they have looked at methylation 
patterns, and it’s just very difficult, because there’s nothing really where you can 
afterwards say, if I do that test I can tell you that cell line goes or not. You can do 
rough things, like you can look at the chromosomal number and if all your chro-
mosome sets are abnormal you don’t have to carry on, but we don’t even do that.
Lovell-Badge. In making iPS cells now people have tried to increase the effi-
ciency, they use various things that can affect chromatin structures. Has anyone 
tried those sort of treatments?
Schnieke. We didn’t, but some people have done something like this. Those 
experiments have been done. Did you do some [Bill Ritchie]?
38
Ritchie. Yeah, we looked at the visual appearance of cells and tried to correlate 
that with what came out at the end, and what we thought were nice cells proved 
to be really the opposite, and some of the cells which looked poor quality actu-
ally gave us some very good results as well. It just proved that we just don’t know 
what is going on.
Colman. Ian, could I ask you what was Keith [Campbell]’s funding?
Wilmut. It was all one block of funding.
Colman. He wasn’t a tenured person at Roslin, was he?
Wilmut. No.
Colman. I ask this because it always struck me that one of the lessons from that 
period was that in a university that could never have happened. No one would 
take on a project like that if it were going to be such a long project with large ani-
mals. You need institutes that have some sort of guaranteed funding over a rela-
tively long term to actually encourage people to take the risk, because no normal 
post-doc would take that project on.
Archibald. Yeah, would be nice to move the [Roslin] Institute to that funding.
Sang. I think you would find that nobody would take on such a project now.
Colman. Is that the case?
Griffin. People come in on a three-year rolling programme. That is the standard 
institute model.
Colman. How do you get people in?
Griffin. That’s been the great success of the Institute, in the past we’ve managed 
to do it. If you think of the breeding experiments on cattle,  they weren’t going to 
get any results for up to nine years, was it?
Sang. I wouldn’t advise anybody to do the same [ laughs ] starting out now.
Griffin. But was that all on three-year contracts?
Sang. It was three to five.
Schnieke. It’s the same for universities, we have the same problem. We get the 
same length of grant for people who do mouse work or just cell culture work, we 
get two to three years.
Colman. How do you persuade people who are just coming in, looking to build 
a career, that get a short-term grant with you. You can’t guarantee they’ll get an-
other grant at the end, and you can’t guarantee they’re going to get any results in 
that first period – how do you actually get them to start?
Archibald. Well, you’re asking that question in the context of Keith . . .  Keith 
jumped the fence and joined you guys [PPL].  And, arguably, with a start-up com-
pany  you could look at a more precarious existence. But I think from what you 
said earlier it rings true that Keith went to Nottingham [in 1999, after leaving 
PPL] not because of the precariousness of the existence, but because he just liked 
the idea of being an academic scientist, and it was obviously a better place for that 
than anywhere else.
Sang. Keith had had a nonstandard career, because he did his PhD later, so 
he probably had fewer options, because it’s very hard to make your career if you 
don’t do a degree, a PhD, a couple of post-docs, in a nice linear fashion.
Ritchie. Just to take a step back, you were talking about the length of some of 
these experiments. When I started at the Stanhope farm, that was an experiment 
that ran for 25 years [ laughs ]: to alter or to look at genetics in large animals, you 
needed 25 generations. But as you say, Helen [Sang], we probably couldn’t do the 
cloning experiments now, because a lot of the equipment that I used was actu-
ally made in our workshop. I haven’t got a workshop [anymore], so it’d be really 
quite difficult doing it, it’d be almost impossible to actually carry out these sort 
of experiments, getting someone else to actually make the equipment that we 
first used, to actually make the pipettes and all the other paraphernalia that we 
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required to do the cloning. It just wouldn’t work at all.
Archibald. But that workshop effort was a joint enterprise between the Institute 
and the University, as far as I recall, and I’m not quite sure the university’s got 
anything like that [today].
Sang. I think the Chemistry Department is about the only place that’s still got 
a workshop.
Whitelaw. Just another general comment here, maybe Angelika can support it, 
Helen as well. It’s not easy to recruit people, post-docs, into this field, and it’s not 
only the duration [of the grants]: there isn’t anywhere for them to go. We don’t 
have open positions aplenty for aspiring group leaders to fill; it’s still quite a small 
community. Having said that, as evidenced by this room, a lot of those groups 
are coming to the end of their careers, and maybe there’ll be opportunities now 
[ laughter ]. 
Colman. You’re talking about dead men’s shoes now.
Whitelaw. But that’s  the real challenge, where do they go? I don’t know how 
many groups we could classify as working with large animals, maybe ten, twelve 
at the most, around the world. Poultry, half of that, where do they go? They go 
into industry.
Lovell-Badge. Various things are starting to happen now, and going to the clin-
ic, do you think that will expand the area, or is it always going to be small?
Whitelaw. Again, personally, I think most of that will go into the industrial en-
vironment.
Sang. I think that, although we went through a very lean period for agricultural 
research  in the past, we came through. It still is very underfunded.
Lovell-Badge. In the UK?
Sang. In the UK and around the world. When you think about food security, 
the research input is relatively low given the challenges that we’re facing.
Archibald. We’ve done the easy bits.
fIGuRe 12. Four sheep 
cloned by Keith Campbell 
and his team at the Univer-
sity of Nottingham from the 
same cell line used to make 
Dolly. The sheep are Debbie, 
Denise, Dianna and Daisy. 
They were made in various 
studies between 2005 and 
2007, and were announced in 
July 2016.  
© University of Nottingham
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Schnieke. Yes, also the attitude of the general public towards GM food. Europe 
has kept the research on that area down. Now, it’s sort of changing a bit, but up 
to now, it’s the biomedical field where things have happened, and much less in 
agriculture.
Whitelaw. I want to back that, one of the reasons why it’s quite good in the 
United Kingdom is that many of the big breeding companies are British, they 
may be international in their way, but they’re British and this helps in our fund-
ing system.
McWhir. Just following on from your comment about the public perceptions 
of GM, it’s interesting that, based on what I read, the basis of most public con-
cern is aspects of genetically-modified crops that don’t apply to farm animals. 
Now, there may be a completely different set of reasons for being frightened of 
genetically-modified farm animals, I would guess around animal welfare issues, 
but it’s a completely different set of issues.
Schnieke. It is different between plants and animals, but on the animal side, like 
you said, it is more animal wellbeing and farming.
Colman. Unless it’s fish like salmon. 
Schnieke. Yeah, but how long did that [approval of transgenic salmon] take? 
With the farm animals, there is a public perception that we’re mistreating the an-
imals, there’s no realistic picture of how agricultural animals are kept, and there 
is a sort of an idealistic vision of farm animals, and not a realistic one.
Griffin. If alpha-1-antitrypsin had worked, I don’t think it would’ve had public 
resistance to it being introduced, so a key thing for the GM movement is to get 
one product that actually works.
Colman. I disagree.
Sang. I do, yes.
Colman. I think with the biomedical [issues], if you say there’s an unmet clinical 
need and you can meet it, then people will think that’s good.
Sang. Yes.
Colman. But with the food, they think, ‘why do we need it’? They will need it, 
probably, when everyone’s starving.
Sang. I give a lot of talks on the chickens and the applications. And there are 
medicines in eggs, really neat, resistance to bird flu, so people can conceptually 
think that these are all good applications, but actually when it comes to it, there’s 
no real push to overcome the resistance to implementing these things. So it’s a 
really complicated thing, and a lot of it in Europe is driven by the lobby groups, 
the NGOs who have the ear of the European parliament. I don’t think it particu-
larly reflects what ‘the people’ want, but they don’t want the new things enough 
to overcome that. It all relates to conflating GM with multinational companies.
Lovell-Badge. But [GM animals] would solve quite a lot of the problems by hav-
ing an organ transplant, right? It’s bizarre.
García-Sancho. Something that strikes me when I read the annual reports of 
the Roslin Institute is that you can see the huge increase of publicity with Dolly, 
and you can track the media attention and how it becomes a lead story, whereas 
Polly receives very little space. If we look at this through the eyes of the pharming 
program, Polly was more like the conclusion of that program, because it was both 
genetically modified and cloned. I wonder why even in the internal publications 
of the Roslin Institute you see that difference in the amount of information. 
Colman. I would say that Polly and Molly were incremental advances, despite 
the huge complexities in using nuclear transfer. Whereas the Dolly thing was a 
huge change.
Sang. But also, you’re looking at the Institute reports. Those final steps weren’t 
ours, they were within PPL. If we were reporting it now that we’re attuned to reg-
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istering the impact of our research, we might have more reach through to things 
that have gone from the Institute to application.
Colman. We didn’t make any money.
Archibald. That’s probably the crunch. These days we are expected to report 
impact of research and that’s generally several years down the track.
Colman. When you say impact, what do you mean by impact?
Archibald. Socio-economic impact or impact on policy.
Colman. What about emotional impact?
Sang. That’s not one of the headings.
Archibald. We continue to talk about the impact of the quantitative geneti-
cist in terms of genetic improvement, we talk about the work that we’ve done in 
terms of detecting genetic variants that affect a certain vulnerability to infectious 
diseases, because we can quantify that they’re making ongoing economic impact. 
At the time, we made a big noise about Dolly and PPL. These days we probably 
wouldn’t repeat that because PPL unfortunately went bust, so that economic im-
pact kind of stopped, as far as the bit that we could track. There are the bits that 
I’m not entirely sure we’ve got our hands on, in terms of the other things that 
happened post-Dolly, but we’re probably not well placed to try and quantify that 
synthesis, what it delivered.
Colman. But if you were a pure research institute or an MRC institute, a major 
publication like that would be recorded very positively, long after. Even if it made 
no money, the impact it had on the way scientists worked elsewhere, a more al-
truistic, if you like, contribution
Sang. Well, we do that, too.
Schnieke. When it was rated Scientific Breakthrough of the Year, I think any 
institute would put it on their [publicity materials].
Sang. You can go down there to the University shop and buy a cuddly toy Dolly.
Lovell-Badge. Dolly the toy sheep, does Roslin get anything from that?
Archibald. The cuddly toy sheep, with its University sweater on [ laughter ], re-
tails at … is it ten pounds?
Sang. Fifteen pounds!
Archibald. Fifteen pounds, and of that nine or ten are going into a fund that will 
be used to support post-docs and students going to conferences. It’s the hottest 
selling item in the University of Edinburgh gift shop, apparently.
Colman. Will I be able to buy one in the airport? 
Sang. No. The shop’s at George Square if you’ve got time.
Lovell-Badge. So at least there is some economic benefit.
Griffin. We did consider whether or not we should trademark Dolly, a long 
while back, and trying to maintain a public image of the Institute that wasn’t 
money grabbing, we made the decision not to.
Schnieke. Do you get a discount if you were involved? [ laughter ]
Archibald. I doubt it.
Sang. Go in the shop and see if you can try it!
Archibald. And there was of course the IKEA opportunity that you turned 
down, Harry.
Griffin. Which one was that?
Archibald. They wanted Dolly to open the IKEA store [ laughter ] and to dye her 
blue and yellow.
Griffin. We also turned down an invitation from Dolly Parton to ship the sheep 
to Dollywood.52 Didn’t think we would get it past the animal welfare committee.
García-Sancho. Maybe it is better to follow up on this over drinks! Before we 
finish, I just wanted to thank you very much for coming here, for making the ef-
fort, for all the contributions. It’s been really enlightening for us. 
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9. Sir John Gurdon is a British developmental biologist who 
cloned a Xenopus laevis frog from a somatic (i.e. non-repro-
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